CN107208075A - 重组酶突变体 - Google Patents

重组酶突变体 Download PDF

Info

Publication number
CN107208075A
CN107208075A CN201580059870.9A CN201580059870A CN107208075A CN 107208075 A CN107208075 A CN 107208075A CN 201580059870 A CN201580059870 A CN 201580059870A CN 107208075 A CN107208075 A CN 107208075A
Authority
CN
China
Prior art keywords
lys
glu
leu
ser
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580059870.9A
Other languages
English (en)
Other versions
CN107208075B (zh
Inventor
E.博马蒂
M.W.凯林格
J.M.鲍特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Link Cambridge Ltd
Illumina Cambridge Ltd
Original Assignee
Link Cambridge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Link Cambridge Ltd filed Critical Link Cambridge Ltd
Publication of CN107208075A publication Critical patent/CN107208075A/zh
Application granted granted Critical
Publication of CN107208075B publication Critical patent/CN107208075B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00Reaction characterised by the enzymatic activity
    • C12Q2521/50Other enzymatic activities
    • C12Q2521/501Ligase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y306/00Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01008ATP diphosphatase (3.6.1.8)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

本文呈现了重组酶以及使用该重组酶的方法和试剂盒,所述重组酶在模式化流动池表面上实现改善的重组酶介导的核酸(如具有单链衔接头区的PCR文库)扩增,从而实现改善的簇扩增。

Description

重组酶突变体
发明背景
重组酶可用于重组酶介导的核酸扩增。例如,重组酶可以促进寡核苷酸靶向DNA靶标,允许通过聚合酶复制DNA。仍然需要具有改善性质的修饰的重组酶。
序列表
本申请与电子格式的序列表一起提交。该序列表作为一个创建于2014年09月26日,大小为98Kb的,命名为IP1264.TXT的文件提供。序列表的电子格式中的信息通过引用以其整体并入本文。
发明概述
本文呈现的是用于改善的重组酶介导的核酸扩增的重组酶。令人惊讶地,本发明人已经鉴定出某些改变的重组酶,其在将核酸接种(seeding)至模式化(patterned)流动池表面中具有实质改善的特点。在某些实施方案中,改变的重组酶改善在模式化流动池表面上接种无PCR文库(PCR-free library)(如具有单链衔接头区的PCR文库),从而实现改善的簇扩增。
在某些实施方案中,所述重组酶是重组UvsX,且包含功能上等同于RB49UvsX氨基酸序列中Pro256的位置处的氨基酸取代。野生型RB49 UvsX氨基酸序列如SEQ ID NO:1所示。在某些实施方案中,所述重组UvsX包含氨基酸序列,该氨基酸序列包含与SEQ ID NO:1至少60%、70%、80%、90%、95%、99%相同的氨基酸,并包含在功能上等同于RB49 UvsX氨基酸序列中Pro256的位置处的氨基酸取代突变。在某些实施方案中,取代突变包含突变为带电荷的残基。在某些实施方案中,取代突变包含突变为碱性残基。在某些实施方案中,取代突变包含与RB49 UvsX氨基酸序列中Pro256Lys同源的突变。
在一些实施方案中,除以上突变外,重组UvsX还可以包含在功能上等同于RB49UvsX氨基酸序列中His63的位置处的取代突变。例如,在某些实施方案中,重组UvsX包含与RB49 UvsX氨基酸序列中His63Ser同源的取代突变。
在一些实施方案中,除以上任何突变外,重组UvsX还可包含选自下组的突变:在C末端添加一个或多个谷氨酸残基;在C末端添加一个或多个天冬氨酸残基;及其组合。
在一些实施方案中,重组UvsX衍生自选自下组的肌病毒科噬菌体:T4、T6、Rb69、Aeh1、KVP40、不动杆菌噬菌体133、气单胞菌噬菌体65、噬蓝藻体P-SSM2、噬蓝藻体PSSM4、噬蓝藻体S-PM2、Rb32、弧菌噬菌体nt-1、Rb16、Rb43,和Rb49。
在一些实施方案中,重组UvsX衍生自选自下组的肌病毒科噬菌体:T2、Rb14、气单胞菌噬菌体25、phi-1、噬菌体31、噬菌体44RR2.8t、噬菌体Rb3、和噬菌体LZ2。
本文还呈现的是重组UvsX,其包含SEQ ID NO:2和22-35中任一项的氨基酸序列。在某些实施方案中,重组UvsX包括氨基酸序列,所述序列包含与SEQ ID NO:2和22-35至少60%、70%、80%、90%、95%、99%相同的氨基酸,且其包含在功能上等同于RB49 UvsX氨基酸序列中Pro256的位置处的氨基酸取代突变。
本文还呈现的是重组UvsX,其包含对包含SEQ ID NO:3-5中任一项的氨基酸序列的半保守域的取代突变(a substitution mutation to the semi-conserved domaincomprising the amino acid sequence of any of SEQ ID NOs:3-5),其中所述取代突变包含选自下组的突变:在位置7处取代为除Phe、Pro、Asp、Glu或Asn以外的任何残基。在某些实施方案中,重组UvsX包含与重组酶(其包含半保守域,该半保守域包含SEQ ID NO:3-5中任一个的氨基酸序列)至少60%、70%、80%、90%、95%、99%相同的氨基酸,并且其中重组UvsX包含选自下组的取代突变:在位置7处突变为除Phe、Pro、Asp、Glu或Asn以外的任何残基。在某些实施方案中,突变包含突变为带电荷的残基。在某些实施方案中,突变包含突变为碱性残基。在某些实施方案中,突变包含在位置7处取代为Lys。
本文还呈现的是重组UvsX,包含对包含SEQ ID NO:6-7中任一项的氨基酸序列的半保守域的取代突变,其中取代突变包含选自下组的突变:在位置12处取代为除Phe、Pro、Asp、Glu或Asn以外的任何残基。在某些实施方案中,重组UvsX包含与重组酶(其包含半保守域,该半保守域包含SEQ ID NO:6-7中任一个的氨基酸序列)至少60%、70%、80%、90%、95%、99%相同的氨基酸,并且其中重组UvsX包含选自下组的突变:在位置12处取代为除Phe、Pro、Asp、Glu或Asn以外的任何残基。在某些实施方案中,突变包含突变为带电荷的残基。在某些实施方案中,突变包含突变为碱性残基。在某些实施方案中,突变包含在位置12取代为Lys。
在一些实施方案中,除以上突变外,重组UvsX还可以包含在功能上等同于RB49UvsX氨基酸序列中His63的位置处的取代突变。例如,在某些实施方案中,重组UvsX包含与在RB49 UvsX氨基酸序列中His63Ser同源的取代突变。
在一些实施方案中,除了以上任何突变外,重组UvsX还可以包含选自下组的突变:在C末端添加一个或多个谷氨酸残基;在C末端添加一个或多个天冬氨酸残基;及其组合。
在一些实施方案中,重组UvsX衍生自选自下组的肌病毒科噬菌体:T4、T6、Rb69、Aeh1、KVP40、不动杆菌噬菌体133、气单胞菌噬菌体65、噬蓝藻体P-SSM2、噬蓝藻体PSSM4、噬蓝藻体S-PM2、Rb32、弧菌噬菌体nt-1、Rb16、Rb43,和Rb49。
在一些实施方案中,重组UvsX衍生自选自下组的肌病毒科噬菌体:T2、Rb14、气单胞菌噬菌体25、phi-1、噬菌体31、噬菌体44RR2.8t、噬菌体Rb3、和噬菌体LZ2。
还呈现的是编码如任何以上实施方案所定义的重组UvsX的核酸分子。本文还呈现的是包含上述核酸分子的表达载体。本文还呈现的是包含上述载体的宿主细胞。
还呈现的是扩增靶核酸分子的重组酶聚合酶扩增方法,其包含以下步骤:(a)将任何以上实施方案的重组UvsX与第一和第二核酸引物接触以形成第一和第二核蛋白引物,其中所述核酸引物包含在其3’端的单链区;(b)将所述第一和第二核蛋白引物与所述靶核酸分子接触,从而在所述第一链的第一部分处形成第一双链结构并且在所述第二链的第二部分处形成第二双链结构,从而所述第一核酸引物和所述第二核酸引物的3’端在相同的双链模板核酸分子上彼此相对定向;(c)用一种或多种聚合酶和dNTP延伸所述第一和第二核酸引物的3’端以产生第一和第二双链核酸和核酸的第一和第二置换链;和(d)通过重复(b)和(c)继续反应,直到达到期望的扩增程度。
在该方法的某些实施方案中,靶核酸分子包含双链核酸。在某些实施方案中,靶核酸分子包含单链核酸。例如,在一些实施方案中,靶核酸包含单链衔接头区。在某些实施方案中,所述方法在重组酶加载蛋白(loading protein)存在下进行。例如,重组酶加载蛋白可选自下组:T4UvsY、大肠杆菌(E.coli)recO、大肠杆菌recR,及其组合。在某些实施方案中,所述方法在选自下组的单链稳定剂的存在下进行:gp32、大肠杆菌SSB蛋白、T4gp32蛋白,及其衍生物。在某些实施方案中,所述方法在选自下组的拥挤剂(crowding agent)的存在下进行:聚乙二醇,聚环氧乙烷,聚苯乙烯,Ficoll,葡聚糖,PVP,和白蛋白,使得所述拥挤剂刺激扩增。
在某些实施方案中,该方法在扩增位点的阵列上进行。在某些实施方案中,每个扩增位点包含多个用于扩增靶核酸的扩增引物。在某些实施方案中,所述扩增位点的阵列包含表面上的特征阵列。例如,所述特征可以是不连续的并由缺少扩增引物的表面的间隙区域分开。在某些实施方案中,扩增位点的阵列包含溶液中的珠粒或表面上的珠粒。在某些实施方案中,扩增位点的阵列包含乳液。在某些实施方案中,等温发生所述方法。
还呈现的是用于进行重组酶聚合酶反应的试剂盒。在某些实施方案中,试剂盒可以包含如上述任何实施方案中所定义的重组UvsX,以及如下一种或多种:单链DNA结合蛋白;DNA聚合酶;dNTP或dNTP和ddNTP的混合物;拥挤剂;缓冲液;还原剂;ATP或ATP类似物;重组酶加载蛋白;第一引物和任选地第二引物。
一个或多个实施方案的细节在附图和下面的描述中阐述。其他特征、目的和优点将从说明书和附图,以及权利要求书中变得显而易见。
附图简述
图1是示意图,其示出了来自以下的UvsX氨基酸序列的比对:肠杆菌噬菌体T4(T4)(SEQ ID NO:8)、肠杆菌噬菌体T6(T6)(SEQ ID NO:9)、不动杆菌噬菌体133(Phage133)(SEQID NO:10)、肠杆菌噬菌体RB69(Rb69)(SEQ ID NO:11)、气单胞菌噬菌体Aeh1(Aeh1)(SEQID NO:12)、气单胞菌噬菌体65(Ae65)(SEQ ID NO:13)、弧菌噬菌体KVP40(Kvp40)(SEQ IDNO:14)、肠杆菌噬菌体RB43(Rb43)(SEQ ID NO:15)、原绿球菌(Prochlorococcus)噬菌体P-SSM2(PSSM2)(SEQ ID NO:16),和原绿球菌噬菌体P-SSM4(PSSM4)(SEQ ID NO:17),如在US2009/0029421的并入材料中阐述。突出显示了位置上和功能上等同于RB49 UvsX氨基酸序列中Pro256的残基,并由三角形符号表示。
图2是示意图,其示出了来自肠杆菌噬菌体RB49(RB49)(SEQ ID NO:1)和肠杆菌噬菌体T4(T4)(SEQ ID NO:8)的UvsX氨基酸序列的比对。突出显示了位置上和/或功能上等同于RB49 UvsX氨基酸序列中Pro256的残基,并由三角形符号表示。
图3A示出了使用T4UvsX制剂接种到模式化流动池上的无PCR文库的簇图像的截图。
图3B示出了使用包含RB49 P256K重组酶的液体制剂接种到模式化流动池上的无PCR文库的簇图像的截图。
图4A示出了使用T4UvsX制剂接种到模式化流动池上的单链(ssDNA)无PCR文库的簇图像的截图。
图4B示出了使用包含RB49 P256K重组酶的液体制剂接种到模式化流动池上的单链无PCR文库的簇图像的截图。
发明详述
本文呈现的是用于改善的重组酶介导的核酸扩增的重组酶。令人惊讶地,本发明人已经鉴定出某些改变的重组酶,其在将核酸接种至模式化流动池表面上中具有实质改善的特点。
如下文更详细地描述的,令人惊讶地,发明人发现,对重组酶中一个或多个残基的一个或多个突变导致在模式化流动池表面上接种DNA文库(如例如具有单链衔接头区的PCR文库)中的深刻的改进,给出改善的簇扩增。
在某些实施方案中,取代突变包含突变为具有带电荷的侧链的残基。例如,在一些实施方案中,带电荷的氨基酸是带正电荷的氨基酸残基。术语“带正电荷的氨基酸残基”指侧链pKa值大于7的亲水性氨基酸,即碱性氨基酸。由于与水合氢离子(hydronium ion)缔合,碱性氨基酸通常在生理pH下具有带正电荷的侧链。天然发生的(遗传编码的)碱性氨基酸包括赖氨酸(Lys,K)、精氨酸(Arg,R)和组氨酸(His,H),而非天然(非遗传编码的,或非标准)碱性氨基酸包括例如鸟氨酸、2,3,-二氨基丙酸、2,4-二氨基丁酸、2,5,6-三氨基己酸、2-氨基-4-胍酸丁酸,和高精氨酸。术语“带负电荷的氨基酸”指天然或非天然氨基酸(不论手性),其除了C末端羧基外包含至少一个额外的带负电荷的基团,如羧基、磷酸根(phosphate),膦酸根(phosphonate),磺酸根(sulfonate)等。
本文还呈现的是包含对重组UvsX的半保守域的取代突变的重组UvsX。如本文所用,术语“半保守域”指重组UvsX中在各种物种间完全保守的,或者至少部分保守的部分。已经令人惊讶地发现半保守域中一个或多个残基的突变影响重组酶活性(特别是在单链模板核酸存在下);导致在重组酶介导的扩增反应中接种和/或扩增的增强。如下面的实施例部分所述,这些突变的重组酶在模式化细胞池表面上接种无PCR文库(如具有单链衔接头区的PCR文库)中具有改善的性能,导致改善的簇扩增。
在一些实施方案中,半保守域包含具有SEQ ID NO:3-7中任一个所示序列的氨基酸。SEQ ID NO:3-7对应于各种物种中半保守域中的残基。SEQ ID NO:3对应于T4UvsX氨基酸序列的残基251-258,其在本文中如SEQ ID NO:8所示。在图1和图2中示出了在半保守域中显示各种物种间的保守的比对。图1中示出的UvsX序列获得自Genbank数据库登录号NP_049656(T4),YP_004300647(噬菌体133);NP_861734(RB69);NP_943894.1(Aeh1);YP_004300858(Ae65);NP_899256(KVP40);YP_239013(RB43);YP_214417(P-SSM2);YP_214708(P-SSM4);以及来自US公开号2009/0029421(T6)。图2是示意图,其示出了来自肠杆菌噬菌体RB49(RB49)(SEQ ID NO:1)和肠杆菌噬菌体T4(T4)(SEQ ID NO:8)的UvsX氨基酸序列的比对。突出显示了位置上和/或功能上等同于RB49 UvsX氨基酸序列中Pro256的残基,并由三角形符号表示。图2中所示的UvsX序列获得自Genbank数据库登录号NP_891595(RB49)和NP_049656(T4)。
令人惊讶地,发现对半保守域中一个或多个残基的突变增加了重组酶的活性,特别是在单链模板核酸存在下,导致重组酶介导的扩增反应中的接种和/或扩增的增强。如下面的实施例部分所述,这些突变的重组酶在模式化细胞池表面接种无PCR文库(如具有单链衔接头区的PCR文库)中具有改善的性能,导致改善的簇扩增。例如,在一些本文呈现的重组UvsX的实施方案中,取代突变包含在SEQ ID NO:3-5中任一个的位置7处突变为除Phe、Pro、Asp、Glu或Asn以外的任何残基取代。在某些实施方案中,重组UvsX包含SEQ ID NO:3-5中任一个的位置7处突变为Lys。在一些本文呈现的重组UvsX的实施方案中,取代突变包含在SEQID NO:6-7中任一个的位置12处突变为除Phe、Pro、Asp、Glu或Asn以外的任何残基。在某些实施方案中,重组UvsX包含SEQ ID NO:6-7中任一个的位置12处突变为Lys。
在一些实施方案中,重组酶是UvsX蛋白。任何噬菌体重组酶可以用于本文呈现的实施方案中,包括例如噬菌体重组酶,如衍生自肌病毒科噬菌体的UvsX或UvsX样重组酶,如例如T4、T6、Rb69、Aeh1、KVP40、不动杆菌噬菌体133、气单胞菌噬菌体65、噬蓝藻体P-SSM2、噬蓝藻体PSSM4、噬蓝藻体S-PM2、Rb32、弧菌噬菌体nt-1、Rb16、Rb43,和Rb49。在某些实施方案中,重组酶是衍生自肌病毒科噬菌体的UvsX或UvsX样重组酶,如例如T2、Rb14、气单胞菌噬菌体25、phi-1、噬菌体31、噬菌体44RR2.8t、噬菌体Rb3、和噬菌体LZ2。对于本领域技术人员来说显而易见的是,其他重组酶蛋白可以用于本文呈现的实施方案中。如下面更详细描述的,可以使用许多本领域已知的方法(如例如BLAST比对)通过与UvsX的同源性来鉴定适合的重组酶蛋白。
“功能等同”意指对照重组酶(在使用完全不同重组酶的研究的情况下)将包含被认为在酶中具有相同的功能作用的其他重组酶的氨基酸位置处发生的氨基酸取代。作为一个例子,T4UvsX中位置257从苯丙氨酸到赖氨酸(F257K)的突变将与RB49 UvsX中位置256从脯氨酸到赖氨酸(P256K)的取代是功能等同的。
通常在两种或更多种不同重组酶中的功能等同取代突变发生在重组酶的氨基酸序列中的同源氨基酸位置。因此,本文使用术语“功能等同”也包含与给定突变“位置上等同”或“同源”的突变,而不考虑突变氨基酸的特定功能是否已知。可以基于序列比对和/或分子建模(modelling)来鉴定两个或更多个不同重组酶的氨基酸序列中的位置等同或同源的氨基酸残基。图1中列出了鉴定位置等同和/或功能等同残基的序列比对的实例,所述图1列出了来自以下的UvsX氨基酸序列的比对:肠杆菌噬菌体T4(T4)(SEQ ID NO:8)、肠杆菌噬菌体T6(T6)(SEQ ID NO:9)、不动杆菌噬菌体133(噬菌体133)(SEQ ID NO:10)、肠杆菌噬菌体RB69(Rb69)(SEQ ID NO:11)、气单胞菌噬菌体Aeh1(Aeh1)(SEQ ID NO:12)、气单胞菌噬菌体65(Ae65)(SEQ ID NO:13)、弧菌噬菌体KVP40(Kvp40)(SEQ ID NO:14)、肠杆菌噬菌体RB43(Rb43)(SEQ ID NO:15)、原绿球菌噬菌体P-SSM2(PSSM2)(SEQ ID NO:16),和原绿球菌噬菌体P-SSM4(PSSM4)(SEQ ID NO:17),如也在US 2009/0029421的并入材料中阐述。图1所示的UvsX序列获自Genbank数据库登录号NP_049656(T4),YP_004300647(噬菌体133);NP_861734(RB69);NP_943894.1(Aeh1);YP_004300858(Ae65);NP_899256(KVP40);YP_239013(RB43);YP_214417(P-SSM2);YP_214708(P-SSM4);以及来自US公开号2009/0029421(T6)。
图2是示意图,其示出了来自肠杆菌噬菌体RB49(RB49)(SEQ ID NO:1)和肠杆菌噬菌体T4(T4)(SEQ ID NO:8)的UvsX氨基酸序列的比对。突出显示了位置上和/或功能上等同于RB49 UvsX氨基酸序列中Pro256的残基,并由三角形符号表示。示于图2的UvsX序列获得自Genbank数据库登录号NP_891595(RB49)和NP_049656(T4)。
位置上等同和/或功能上等同的残基可以通过将那些序列与参考序列(例如T4和RB49)的序列进行比对来对任何数量的其他UvsX序列中的一个或多个测定。作为非限制性的示例,来自聚球藻(Synechococcus)噬菌体S-PM2、肠杆菌噬菌体RB32、弧菌噬菌体nt-1、肠杆菌噬菌体RB16的UvsX序列如SEQ ID NOs:18-21所列,并获得自Genbank数据库登录号YP_195169.1;YP_802982.1;YP_008125207.1;YP_003858336.1,其可以与参考UvsX序列如T4UvsX(SEQ ID NO:8)和RB49 UvsX(SEQ ID NO:1)比对,并且鉴定了位置上等同和/或功能上等同的残基。例如,示于下表的残基被鉴定为与RB49 UvsX氨基酸序列中Pro256在位置上等同和/或功能上等同。本领域技术人员将容易理解,其他UvsX蛋白的位置上等同和/或功能上等同的位置可以按照以下类似的方法来确定。
上文描述的重组UvsX蛋白可以包含已知增强重组酶活性、稳定性或任何其它所需性质的一个或多个方面的其它取代突变。例如,在一些实施方案中,除了上述任何突变之外,重组UvsX还可包含与RB49 UvsX氨基酸序列中His63功能上等同的位置的取代突变,如本领域已知并以US 2009/0029421的披露为例,其通过引用以其整体并入。例如,在某些实施方案中,重组UvsX包含与RB49 UvsX氨基酸序列中His63Ser同源的取代突变。
在一些实施方案中,除了以上任何突变之外,与野生型重组酶相比,重组UvsX可包含额外的取代、缺失和/或添加突变。可以在位置的一个或多个处进行多种取代突变中的任一种,如本领域已知并以2009/0029421的并入材料示例。例如,在一些实施方案中,除以上突变外,重组UvsX还可包含选自下组的突变:在C末端添加一个或多个谷氨酸残基;在C末端添加一个或多个天冬氨酸残基;及其组合。
使重组酶突变
在本公开中任选使用各种类型的诱变,例如修饰重组酶以产生变体,如根据重组酶模型和模型预测,或使用随机或半随机突变方法。通常,任何可用的诱变程序可用于制备重组酶突变体。此类诱变程序任选地包括对突变体核酸和多肽选择感兴趣的一种或多种活性(如,在固体支持物上的增强的接种和/或扩增)。可以使用的程序包括但不限于:定点诱变(site-directed point mutagenesis)、随机点诱变、体外或体内同源重组(DNA改组和组合重叠PCR)、使用含尿嘧啶的模板进行诱变、寡核苷酸指导的诱变(oligonucleotide-directed mutagenesis)、硫代磷酸酯修饰的DNA诱变、使用有缺口的双链体DNA进行诱变、点错配修复、使用修复缺陷宿主菌株的诱变、限制性选择和限制性纯化、缺失诱变、全基因合成诱变(mutagenesis by total gene synthesis)、简并PCR、双链断裂修复,以及技术人员已知的许多其他方法。用于突变的起始重组酶可以是本文所述的任何一种,包括可用重组酶突变体,如那些在例如US 2009/0029421中鉴定的,其通过引用以其整体并入本文。
任选地,诱变可以通过来自天然存在的重组酶分子,或已知改变的或突变的重组酶(如使用如先前参考文献中所述的现有突变体重组酶)的已知信息,如序列、序列比对、物理特性、晶体结构和/或等引导,如上所述。然而,在另一类实施方案中,修饰可以是基本上随机的(如作为经典或"家族"DNA改组,例如参见Crameri et al.(1998)"DNA shufflingof a family of genes from diverse species accelerates directed evolution"Nature 391:288-291)。
关于突变形式(formats)的额外信息可参见:Sambrook等人,MolecularCloning--A Laboratory Manual(3rd Ed.),Vol.1-3,Cold Spring Harbor Laboratory,Cold Spring Harbor,N.Y.,2000("Sambrook");Current Protocols in MolecularBiology,F.M.Ausubel等人,eds.,Current Protocols,a joint venture between GreenePublishing Associates,Inc.and John Wiley&Sons,Inc.,(通过2011补入)("Ausubel"))和PCR Protocols A Guide to Methods and Applications(Innis等人编)AcademicPress Inc.San Diego,Calif.(1990)("Innis")。以下引用的出版物和参考文献提供了关于突变形式的额外细节:Arnold,Protein engineering for unusual environments,Current Opinion in Biotechnology4:450-455(1993);Bass等人,Mutant Trprepressors with new DNA-binding specificities,Science 242:240-245(1988);Bordoand Argos(1991)Suggestions for"Safe"Residue Substitutions in Site-directedMutagenesis 217:721-729;Botstein&Shortle,Strategies and applications of invitro mutagenesis,Science229:1193-1201(1985);Carter等人,Improvedoligonucleotide site-directed mutagenesis using M13vectors,Nucl.Acids Res.13:4431-4443(1985);Carter,Site-directed mutagenesis,Biochem.J.237:1-7(1986);Carter,Improved oligonucleotide-directed mutagenesis using M13vectors,Methodsin Enzymol.154:382-403(1987);Dale等人,Oligonucleotide-directed randommutagenesis using the phosphorothioate method,Methods Mol.Biol.57:369-374(1996);Eghtedarzadeh&Henikoff,Use of oligonucleotides to generate largedeletions,Nucl.Acids Res.14:5115(1986);Fritz等人,Oligonucleotide-directedconstruction of mutations:a gapped duplex DNA procedure without enzymaticreactions in vitro,Nucl.Acids Res.16:6987-6999(1988);Grundstrom等人,Oligonucleotide-directed mutagenesis by microscale`shot-gun`gene synthesis,Nucl.Acids Res.13:3305-3316(1985);Hayes(2002)Combining Computational andExperimental Screening for rapid Optimization of Protein Properties PNAS99(25)15926-15931;Kunkel,The efficiency of oligonucleotide directedmutagenesis,in Nucleic Acids&Molecular Biology(Eckstein,F.and Lilley,D.M.J.eds.,Springer Verlag,Berlin))(1987);Kunkel,Rapid and efficient site-specific mutagenesis without phenotypic selection,Proc.Natl.Acad.Sci.USA 82:488-492(1985);Kunkel等人,Rapid and efficient site-specific mutagenesiswithout phenotypic selection,Methods in Enzymol.154,367-382(1987);Kramer等人,The gapped duplex DNA approach to oligonucleotide-directed mutationconstruction,Nucl.Acids Res.12:9441-9456(1984);Kramer&Fritz Oligonucleotide-directed construction of mutations via gapped duplex DNA,Methods inEnzymol.154:350-367(1987);Kramer等人,Point Mismatch Repair,Cell 38:879-887(1984);Kramer等人,Improved enzymatic in vitro reactions in the gapped duplexDNA approach to oligonucleotide-directed construction of mutations,Nucl.AcidsRes.16:7207(1988);Ling等人,Approaches to DNA mutagenesis:an overview,AnalBiochem.254(2):157-178(1997);Lorimer and Pastan Nucleic Acids Res.23,3067-8(1995);Mandecki,Oligonucleotide-directed double-strand break repair inplasmids of Escherichia coli:a method for site-specific mutagenesis,Proc.Natl.Acad.Sci.USA,83:7177-7181(1986);Nakamaye&Eckstein,Inhibition ofrestriction endonuclease Nci I cleavage by phosphorothioate groups and itsapplication to oligonucleotide-directed mutagenesis,Nucl.Acids Res.14:9679-9698(1986);Nambiar等人,Total synthesis and cloning of a gene coding for theribonuclease S protein,Science 223:1299-1301(1984);Sakamar and Khorana,Totalsynthesis and expression of a gene for the a-subunit of bovine rod outersegment guanine nucleotide-binding protein(transducin),Nucl.Acids Res.14:6361-6372(1988);Sayers等人,Y-T Exonucleases in phosphorothioate-basedoligonucleotide-directed mutagenesis,Nucl.Acids Res.16:791-802(1988);Sayers等人,Strand specific cleavage of phosphorothioate-containing DNA by reactionwith restriction endonucleases in the presence of ethidium bromide,(1988)Nucl.Acids Res.16:803-814;Sieber等人,Nature Biotechnology,19:456-460(2001);Smith,In vitro mutagenesis,Ann.Rev.Genet.19:423-462(1985);Methods inEnzymol.100:468-500(1983);Methods in Enzymol.154:329-350(1987);Stemmer,Nature370,389-91(1994);Taylor等人,The use of phosphorothioate-modified DNA inrestriction enzyme reactions to prepare nicked DNA,Nucl.Acids Res.13:8749-8764(1985);Taylor等人,The rapid generation of oligonucleotide-directedmutations at high frequency using phosphorothioate-modified DNA,Nucl.AcidsRes.13:8765-8787(1985);Well等人,Importance of hydrogen-bond formation instabilizing the transition state of subtilisin,Phil.Trans.R.Soc.Lond.A 317:415-423(1986);Well等人,Cassette mutagenesis:an efficient method forgeneration of multiple mutations at defined sites,Gene 34:315-323(1985);Zoller&Smith,Oligonucleotide-directed mutagenesis using M 13-derived vectors:an efficient and general procedure for the production of point mutations inany DNA fragment,Nucleic Acids Res.10:6487-6500(1982);Zoller&Smith,Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13vectors,Methods in Enzymol.100:468-500(1983);Zoller&Smith,Oligonucleotide-directedmutagenesis:a simple method using two oligonucleotide primers and a single-stranded DNA template,Methods in Enzymol.154:329-350(1987);Clackson等人(1991)"Making antibody fragments using phage display libraries"Nature 352:624-628;Gibbs et al.(2001)"Degenerate oligonucleotide gene shuffling(DOGS):amethod for enhancing the frequency of recombination with family shuffling"Gene 271:13-20;和Hiraga and Arnold(2003)"General method for sequence-independent site-directed chimeragenesis:J.Mol.Biol.330:287-296。许多以上方法的额外细节可以在Methods in Enzymology Volume 154中找到,该文献也描述了用于各种诱变方法的故障查找问题的有用控制。
制备和分离重组的重组酶
通常,编码如本文呈现的重组酶的核酸可通过以下方法制备:克隆、重组、体外合成、体外扩增和/或其他可用方法。多种重组方法可用于表达编码本文呈现的重组酶的表达载体。制备重组核酸、表达和分离表达产物的方法是公知的并描述于现有技术中。本文描述了多个示例性的突变和突变的组合,以及用于设计所期望突变的策略。
突变、重组和体外核酸操作方法(包括克隆、表达、PCR等)的其他有用参考文献包括:Berger and Kimmel,Guide to Molecular Cloning Techniques,Methods inEnzymology volume 152Academic Press,Inc.,San Diego,Calif.(Berger);Kaufman等人(2003)Handbook of Molecular and Cellular Methods in Biology and MedicineSecond Edition Ceske(编)CRC Press(Kaufman);和The Nucleic Acid ProtocolsHandbook Ralph Rapley(编)(2000)Cold Spring Harbor,Humana Press Inc(Rapley);Chen等人(编)PCR Cloning Protocols,Second Edition(Methods in MolecularBiology,volume 192)Humana Press;和在Viljoen等人(2005)Molecular Diagnostic PCRHandbook Springer,ISBN 1402034032。
此外,商业上可获得用于从细胞纯化质粒和其他相关核酸的多种试剂盒(例如参见EasyPrep.TM.,FlexiPrep.TM.两者来自Pharmacia Biotech;来自Stratagene的StrataClean.TM.;和来自Qiagen的QIAprep.TM.)。可进一步操作任何分离的和/或纯化的核酸以产生其他核酸,用于转染细胞、整合入相关载体以感染生物体用于表达和/或等等。典型的克隆载体含有转录和翻译终止子、转录和翻译起始序列,以及可用于调节特定靶核酸表达的启动子。载体任选地包含通用表达盒,该表达盒包含至少一个独立终止子序列、允许盒在真核生物,或原核生物,或两者中复制的序列(如穿梭载体),和用于原核和真核系统两者的选择标记物。载体适用于原核生物,真核生物或两者的复制和整合。
其他有用的参考文献(例如用于分离和培养细胞(例如用于后续核酸分离))包括Freshney(1994)Culture of Animal Cells,a Manual of Basic Technique,thirdedition,Wiley-Liss,New York及其所引用的参考文献;Payne et al.(1992)Plant Celland Tissue Culture in Liquid Systems John Wiley&Sons,Inc.New York,N.Y.;Gamborg and Phillips(编)(1995)Plant Cell,Tissue and Organ Culture;FundamentalMethods Springer Lab Manual,Springer-Verlag(Berlin Heidelberg New York)以及Atlas and Parks(编)The Handbook of Microbiological Media(1993)CRC Press,BocaRaton,Fla。
编码本文公开的重组重组酶的核酸也是本文所呈现的实施方案的特征。特定的氨基酸可以由多个密码子编码,并且某些翻译系统(例如原核或真核细胞)通常表现出密码子偏好,例如不同的生物体往往偏好编码相同氨基酸的几个同义密码子之一。因此,本文呈现的核酸可任选地“密码子优化”,这意味着合成核酸以包括密码子,该密码子为用于表达表达重组酶的特定翻译系统所偏好。例如,当需要在细菌细胞(或甚至是特定的细菌菌株)中表达重组酶时,可以合成核酸以包括在该细菌细胞的基因组中最常见的密码子,用于有效表达重组酶。当希望在真核细胞中表达重组酶时,可以采用类似的策略,例如核酸可以包括真核细胞所偏好的密码子。
已知多种蛋白分离和检测方法,并且所述方法可用于分离重组酶(例如从表达本文呈现的重组的重组酶的重组细胞培养物中分离)。多种分离和检测蛋白的方法在本领域中是公知的,包括,如下中列出的那些方法:R.Scopes,Protein Purification,Springer-Verlag,N.Y.(1982);Deutscher,Methods in Enzymology Vol.182:Guide to ProteinPurification,Academic Press,Inc.N.Y.(1990);Sandana(1997)Bioseparation ofProteins,Academic Press,Inc.;Bollag等人(1996)Protein Methods,2.sup.nd EditionWiley-Liss,NY;Walker(1996)The Protein Protocols Handbook Humana Press,NJ,Harris and Angal(1990)Protein Purification Applications:A Practical ApproachIRL Press at Oxford,Oxford,England;Harris and Angal Protein PurificationMethods:A Practical Approach IRL Press at Oxford,Oxford,England;Scopes(1993)Protein Purification:Principles and Practice 3.sup.rd Edition SpringerVerlag,NY;Janson and Ryden(1998)Protein Purification:Principles,HighResolution Methods and Applications,Second Edition Wiley-VCH,NY;以及Walker(1998)Protein Protocols on CD-ROM Humana Press,NJ;以及其中所引用的参考文献。关于蛋白质纯化和检测方法的其他细节可以在Satinder Ahuja编,Handbook ofBioseparations,Academic Press(2000)中找到。
使用方法
本文呈现的改变的重组酶可用于重组酶介导的扩增程序,如重组酶聚合酶扩增(RPA)技术。简单来说,可以通过使靶核酸与重组酶和对靶核酸分子特异性的单链核酸引物接触来引发RPA。然后,可以通过聚合酶,如在dNTP的存在下能够链置换以产生双链靶核酸分子和核酸分子的置换链的聚合酶延长杂交的引物。进一步扩增可以通过重组酶介导的引物靶向至核酸分子的置换链以及引物的延伸以产生双链核酸分子来实现。可通过将上述组分与例如重组酶加载因子(recombinase-loading factors)、特异性链置换聚合酶以及强健的(robust)能量再生系统的组合调控RPA程序。可以容易地适用于与本公开的重组UvsX蛋白一起使用的示例性RPA程序、系统和组分记载于例如US专利号8,071,308;7,399,590,7,485,428,7,270,981,8,030,000,7,666,598,7,763,427,8,017,399,8,062,850,和7,435,561,其各自通过引用并入本文。
在一些实施方案中,可以使用动力学排除扩增(kinetic exclusionamplification)(KEA)(其也称为排除扩增(ExAmp))来进行等温扩增。可以使用利用动力学排除的方法制备本公开的核酸文库。当过程以足够快的速率发生以有效地排除另一种事件或过程发生时,可以发生动力学排除。举例来说,制备核酸阵列,其中将来自溶液的靶核酸随机接种到阵列的位点,并在扩增过程中产生靶核酸的拷贝,以对每个接种位点填充容量(capacity)。根据本公开的动力学排除方法,接种和扩增步骤可以在扩增速率超过接种速率的条件下同时进行。因此,在已经由第一靶核酸接种的位点制备拷贝的相对较快的速率将有效地将第二核酸排除在接种扩增位点外。动力学排除扩增方法可以如US申请公开No.2013/0338042公开内容中详细描述的那样进行,其通过引用以其整体并入本文。
在一些实施方案中,扩增的靶核酸是完全双链的。在一些实施方案中,扩增的靶核酸包含双链核酸的区域,并且还包含具有单链核酸的区域。在某些实施方案中,靶核酸包含一个或多个叉状衔接头,其在文库片段的每个末端具有约5,10,15,20,25,30,35,40或超过约40个碱基的单链序列的区域。叉状衔接头的设计和使用更为详细地描述于美国专利号7,742,463和8,563,748的公开中,其通过引用以其整体并入本文。
动力学排除可以利用用于制备靶核酸的第一拷贝的相对缓慢的速率对用于制备靶核酸或第一拷贝的后续拷贝的相对快的速率。在上一段的例子中,动力学排除由于以下而发生:靶核酸接种的相对缓慢的速率(例如,相对缓慢的扩散或转运)对发生扩增以填充具有核酸种子的拷贝的位点的相对快速速率。在另一个示例性的实施方案中,动力学排除可以由于以下而发生:已经接种位点的靶序列的第一拷贝的形成延迟(例如延迟或缓慢活化)对制备后续拷贝以填充位点的相对快速速率。在该实例中,单个位点可能已经接种了几种不同的靶核酸(例如,几个靶核酸可以在扩增前在每个位点存在)。然而,可以随机激活用于任何给定靶核酸的第一拷贝形成,使得第一拷贝形成的平均速率相较于生成随后拷贝的速率而言是相对缓慢的。在这种情况下,尽管单个位点可能已经接种了几种不同的靶核酸,动力学排除将仅允许扩增那些靶核酸之一。更为具体地,一旦第一靶核酸已经被激活用于扩增,所述位点将用其拷贝迅速填充容量,从而防止在该位点产生第二靶核酸的拷贝。
扩增试剂可以包括促进扩增子形成,并且在某些情况下增加扩增子形成的速率的其它成分。重组酶(如例如UvsX)可以通过允许重复入侵/延伸来促进扩增子形成。更为具体地,重组酶可以促进聚合酶对靶核酸的侵入和通过聚合酶使用靶核酸作为扩增子形成的模板延伸引物。该过程可以作为锁式反应重复,其中从每轮入侵/延伸产生的扩增子在随后的一轮中充当模板。由于不需要变性循环(如经由加热或化学变性),过程可以比标准PCR更为快速发生。因此,可以等温进行重组酶促进的扩增。通常期望在重组酶促进的扩增试剂中包括ATP或其他核苷酸(或在一些情况下为其不可水解的类似物)以促进扩增。重组酶和单链结合(SSB)蛋白的混合物特别有用,因为SSB可进一步促进扩增。用于重组酶促进的扩增的示例性的配制剂包括那些市售的配制剂,如TwistDx的TwistAmp试剂盒(Cambridge,UK)。重组酶促进扩增试剂的有用组分以及反应条件列于US5,223,414和US 7,399,590中,每个通过引用并入本文。
序列比对、同一性和同源性
术语“相同的”或“百分比同一性”,在两个或更多个核酸或多肽序列的语境中,是指在为了最大对应性而比较和比对时,相同的两个或更多个序列或亚序列或者具有相同的氨基酸残基或核苷酸的规定百分比,如使用下文描述的序列比较算法之一(或技术人员可用的其他算法)或通过视觉检查测量的。
短语“实质上相同”,在两个核酸或多肽(如编码重组酶的DNA或重组酶的氨基酸序列)的语境中,是指为了最大对应性而比较和比对时具有至少60%,约80%、约90-95%、约98%、约99%或更多的核苷酸或氨基酸残基同一性的两个或更多个序列或亚序列,如使用序列比较算法或通过视觉检查测量。通常认为所述“实质性相同”序列是“同源的”,而不参考实际的祖先。优选地,“实质性同一性”存在于长度为至少大约50个残基的序列的区域里,更优选地在至少大约100个残基的区域里,以及最优选地,该序列在至少大约150个残基里或在要比较的序列的全长里实质上相同。
当蛋白质和/或蛋白质序列天然地或人工地衍生自共同的祖先蛋白质或蛋白质序列时,它们是“同源的”。类似地,当核酸和/或核酸序列天然地或人工地衍生自共同的祖先核酸或核酸序列时,它们是同源的。同源性通常由两个或更多个核酸或蛋白质(或其序列)之间的序列相似度推断。可用于建立同源性的序列之间相似度的精确百分比随讨论的核酸和蛋白质而变化,但常规地使用超过50,100,150或更多残基至少25%的序列相似度建立同源性。较高水平的序列相似度(如30%,40%,50%,60%,70%,80%,90%,95%,或99%或更高)也可用于建立同源性。用于确定序列相似度百分比的方法(如使用默认参数的BLASTP和BLASTN)在本文中描述并且是通常可获得的。
对于序列比对和同源性确定,通常一个序列作用为比较测试序列的参考序列。当使用序列比较算法时,测试和参考序列被输入到计算机中,指定子序列坐标(如果必要),并且指定序列算法程序参数。然后,序列比较算法基于指定的程序参数来计算测试序列相对于参考序列的百分比序列同一性。
可以进行用于比较的最佳序列比对,例如通过Smith&Waterman,Adv.Appl.Math.2:482(1981)的局部同源性算法,通过Needleman&Wunsch,J.Mol.Biol.48:443(1970)的同源比对算法,通过Pearson&Lipman,Proc.Nat'l.Acad.Sci.USA 85:2444(1988)的寻找相似度方法,对这些算法的计算机化实现(在Wisconsin Genetics软件包中的GAP,BESTFIT,FASTA,和TFASTA,Genetics Computer Group,575Science Dr.,Madison,Wis.),或通过视觉检查(一般参见Current Protocols in Molecular Biology,Ausubel等人编,Current Protocols,a joint venture between Greene Publishing Associates,Inc.and John Wiley&Sons,Inc.,到2004年补充)。
适合于测定百分比序列同一性和序列相似度的算法的一个实例为BLAST算法,其描述于Altschul等人,J.Mol.Biol.215:403-410(1990)中。进行BLAST分析的软件可通过National Center for Biotechnology Information公开获得。这个算法包括首先通过鉴定询问序列中的W长度的短词来鉴定高得分序列对(HSP),所述询问序列当与数据库序列中相同长度的词比对时匹配或满足正值阈值得分T。T是指临近词得分阈值(Altschul等人,如上)。这些最初的临近词命中作用为启动搜索以寻找更长的包含它们的HSP。词命中然后在两个方向上沿着每个序列延伸,远到可增加累积比对得分。对于核苷酸序列,累积得分以M参数(一对匹配残基的奖励得分;总是大于0)和N(不匹配残基的惩罚得分;总是小于0)来计算。对于氨基酸序列,用得分矩阵来计算累计得分。当下述情况时停止每个方向上的词命中的延伸:累积比对得分从其所达到的最大值下降数量X;由于一个或多个负得分残基比对的积累,累积得分到达零或以下;或者,达到任何一个序列的末端。BLAST算法参数W,T和X决定了比对的敏感性和速度。BLASTN程序(对核苷酸序列来说)使用词长度(W)为11,期望值(E)为10,截留为100,M=5,N=-4,以及对两条链的比较作为默认。对于氨基酸序列,BLASTP程序使用词长度(W)为3,期望值(E)为10以及BLOSUM62得分矩阵作为默认(参见Henikoff&Henikoff(1989)Proc.Natl.Acad.Sci.USA 89:10915)。
除了计算序列同一性百分比,BLAST算法也进行两个序列间相似度的统计学分析(参见例如,Karlin&Altschul,Proc.Nat'l.Acad.Sci.USA 90:5873-5787(1993))。BLAST算法所提供的相似度的一种测量为最小总概率(smallest sum probability)(p(N)),其提供了两个核苷酸或氨基酸序列之间的匹配偶然发生的概率的指示。例如,当测试核酸与参考核酸的比较中的最小总概率小于大约0.1,更优选地小于大约0.01,最优选地小于大约0.001时,此核酸被认为是与参考序列相似。
编码改变的重组酶的核酸
本文还呈现的是编码本文呈现的改变的重组酶的核酸分子。对于任意给定的改变的重组酶(其是已知氨基酸序列以及优选地还有编码重组酶的野生型核苷酸序列的重组酶的突变形式),可以根据分子生物学的基本原理获得编码突变体的核苷酸序列。例如,鉴于编码RB49 UvsX重组酶的野生型核苷酸序列是已知的,可以使用标准遗传密码推断编码具有一个或多个氨基酸取代的任何给定的突变型RB49 UvsX的核苷酸序列。类似地,可以容易地衍生核苷酸序列,用于其他重组酶的突变体形式,如例如T4、T6、Rb69、Aeh1、KVP40、不动杆菌噬菌体133、气单胞菌噬菌体65、噬蓝藻体P-SSM2、噬蓝藻体PSSM4、噬蓝藻体S-PM2、Rb32、弧菌噬菌体nt-1、Rb16、Rb43、T2、Rb14、气单胞菌噬菌体25、phi-1、噬菌体31、噬菌体44RR2.8t,噬菌体Rb3,和噬菌体LZ2等。然后可以使用本领域已知的标准分子生物学技术构建具有所需核苷酸序列的核酸分子。
根据本文呈现的实施方式,定义的核酸不仅包括相同的核酸,而且还包括任何次要的碱基变异,包括特别是在由于保守氨基酸取代中的简并密码子而导致同义密码子的情况下的取代(规定相同氨基酸残基的不同密码子)。术语“核酸序列”也包括与关于碱基变异给出的任何单链序列的互补序列。
有利地,本文所述的核酸也可以被包括在合适的表达载体中以在合适的宿主中表达从其编码的重组酶蛋白。将克隆的DNA掺入合适的表达载体中用于随后转化所述细胞并随后选择转化的细胞是本领域技术人员熟知的,如提供于Sambrook等人(1989),Molecularcloning:A Laboratory Manual,Cold Spring Harbor Laboratory中,其以其整体通过引用并入。
此类表达载体包括下述载体,其具有可操作地连接于调节序列的根据本文呈现的实施方案的核酸,所述调节序列能够实现所述DNA片段的表达,如启动子区域。术语“可操作地连接”是指并列位置,其中所描述的组件处于允许它们以其预期方式发挥作用的关系中。可以将此类载体转化到合适的宿主细胞中以提供根据本文呈现的实施方案的蛋白质表达。
核酸分子可以编码成熟蛋白或具有原序列(prosequence)的蛋白,包括编码在前蛋白上的前导序列的,所述前蛋白然后由宿主细胞切割以形成成熟蛋白。载体可以是(例如)提供有复制起点,以及任选地用于表达所述核苷酸的启动子和任选地启动子的调节子的质粒、病毒或噬菌体。载体可以含有一个或多个选择性标记物,如例如抗生素抗性基因。
表达所需的调控元件包括启动子序列以结合RNA聚合酶并以引导适当水平的转录起始以及还包括用于核糖体结合的翻译起始序列。例如,细菌表达载体可以包括启动子,如lac启动子和用于翻译起始,Shine-Dalgarno序列,以及起始密码子AUG。类似地,真核表达载体可以包括对于RNA聚合酶II的异源或同源启动子、下游聚腺苷酸化信号、启动密码子AUG,和用于核糖体分离的终止密码子。此类载体可以商业获得或由本领域公知的方法描述的序列组装。
可以通过在载体中包含增强子序列来优化由高等真核生物的编码重组酶的DNA的转录。增强子是作用于启动子以提高转录水平的DNA的顺式作用元件。除了可选择的标记物之外,载体通常还包括复制起点。
实施例
实施例1
本实施例提供了在模式化流动池表面接种无PCR文库用于改善的簇扩增的方法。在一个实施方案中,本发明的方法使用接种制剂,其包括包含上述突变的UvsX,例如包含Pro256Lys的RB49 UvsX(如本文中意以SEQ ID NO:2所示,本文称为“RB49 P256K”)。令人惊讶地发现,使用其进行的重组酶介导的扩增实质性改善了将具有单链衔接头区的PCR文库接种到模式化流动池表面上。在另一个实施方案中,本发明的方法使用接种制剂,其包括相对高浓度的DNA聚合酶(例如eBsu聚合酶)与RB49 P256K重组酶的组合。
为了评估RB49 P256K制剂在将无PCR文库接种到模式化流动池表面上的功效,使用DNA无PCR样本制备物试剂盒(Illumina,Inc.)生成无PCR文库。使用文库制备试剂盒生成的无PCR文库具有叉状衔接头,其在文库片段的每个末端带有约40个碱基的单链序列的区域。
图3A示出了使用含T4UvsX重组酶(如本文中以SEQ ID NO:8所示,本文称为“T4UvsX”)的标准制剂接种到模式化流动池上的无PCR文库的簇图像的截图100。图3B示出了使用包含RB49 P256K重组酶的液体制剂接种到模式化流动池上的无PCR文库的簇图像的截图150。在该实施例中,将T4UvsX制剂或RB49 P256K制剂与文库混合至100pM终浓度,冲到流动池上,并在cBot上于38℃下孵育。在1小时的孵育期后,将温度降至20℃并且用HT2洗涤缓冲液(Illumina)洗涤流动池。用0.1M Tris/0.1M抗坏血酸钠中的Green(LifeTechnologies)的1:5,000稀释液对簇染色,并且在荧光显微镜上成像。参见图3A,通过用标准制剂(如T4UvsX)将无PCR文库接种到模式化流动池所生成的簇浓度是相对稀疏的。参见图3B,通过使用包含RB49 P256K重组酶的制剂将无PCR文库接种到模式化流动池所生成的簇浓度是显著改善的。
图4A示出了使用标准T4UvsX制剂接种到模式化流动池上的单链(ssDNA)无PCR文库的簇图像的截图200。图4B示出了使用包含RB49 P256K重组酶的液体制剂接种到模式化流动池上的单链无PCR文库的簇图像的截图250。在该实施例中,使用NaOH变性双链无PCR文库并随后在50pM的浓度下接种到模式化流动池上。参见图4A,通过用标准制剂(如T4UvsX)将ssDNA,无PCR文库接种到模式化流动池上所生成的簇浓度是相对稀疏的。参见图4B,通过使用包含RB49 P256K重组酶的制剂将ssDNA无PCR文库接种到模式化流动池上所生成的簇浓度是显著改善的。
实施例2
使用RB49 P256K突变体的改善的扩增
本实施例描述了本文所述的具有和不具有P256K突变的重组酶之间的扩增性能的比较。为了本实施例的目的,“对照”RB49 UvsX(如SEQ ID NO:1所示)还包含H63S突变。通过进一步突变该对照以在位置256处携带Lys残基而产生P256K突变体,如SEQ ID NO:2所示。
如上文实施例1所述,在cBot上使用对照或P256K突变体进行模式化流动池上的无PCR文库的成簇(Clustering)。然后,在HiSeq装置(Illumina,Inc.)上进行测序,并且分析测序结果以确定通常在以前的测序数据中呈现较差的多个区域的可呼叫性(callability)。
可呼叫性是正确呼叫单核苷酸多态性(SNP)的位点的分数的测量。理想情况下,此值为1(即100%),意味着在特定类型区域(即高GC等)内的100%位点,正确呼叫SNP。覆盖率是具有覆盖率>n的位点分数的测量,其中n通常是30x(即人类基因组的标准覆盖率)。fosmid启动子是一组100个基因启动子,其在先前的测序数据中被鉴定为呈现较差的。将启动子克隆入fosmid载体中。高GC区域可以定义为具有至少100bp的区域,其中GC含量等于或超过75%(N50(G+C≥0.75)100N50)。大量GC的区域可以定义为具有至少100bp的GC,其中GC含量等于或大于85%(N50(G+C≥0.85)100N50)。低GC区域可以定义为至少100bp的区域,其中GC含量等于或小于40%(N50(G+C≥0.40)100N50)。高AT区可以被定义为具有至少100bp的区域,其中AT含量等于或超过75%(N50(A+T≥0.75)100N50),下采样至约50k区域。可以将大量AT的区域定义为具有至少100bp的区域,其中AT含量等于或大于85%(N50(A+T≥0.85)100N50),下采样至约50k区域。AT二核苷酸重复区可以被定义为包括长的ATAT重复延伸的区域。
对于对照与P256K突变体的可呼叫性比较表明与对照相比,P256K突变体在fosmid启动子区域、高GC、大量GC、低GC、高AT、大量AT,和AT二核苷酸重复区的一个或多个中显示了出乎预料的且显著的改善。
实施例3
使用具有与P256K同源的突变的突变体的改善扩增
对于其他重组酶,重复上文在实施例2中所述的性能比较。在本实施例中,通过修饰野生型重组酶以包含与RB49中的H63S同源的突变来产生“对照”重组酶,如在下表的“对照”栏列出。通过进一步修饰对照以携带与RB49中P256K同源的突变来产生“P256K同系物”突变体,如在下表的“P256K同系物”栏列出。
例如,对于T6UvsX,通过修饰野生型T6UvsX(SEQ ID NO:9)以携带H66S突变来生成对照。进一步修饰P256K同系物以携带H66S和F259K突变两者。
使用对照或P256K突变体,如上文实施例1所述在cBot进行模式化流动池上的无PCR文库的成簇(Clustering)。然后,在HiSeq仪(Illumina,Inc.)上进行测序,并且如实施例2中所述分析测序结果,以确定通常在先前测序数据中较差呈现的多种区域的可呼叫性。
对于对照与P256K同系物突变体的可呼叫性的比较表明与对照相比,P256K同系物突变体在fosmid启动子区域、高GC、大量GC、低GC、高AT、大量AT,和AT二核苷酸重复区的一个或多个中显示出乎预料的且显著的改善。
在本申请中,已经引用了各种出版物,专利和/或专利申请。这些出版物的全部内容通过引用并入本申请中。
术语“包括”旨在是开放式的,不仅包括列举的元件,而且还包括任何另外的元件。
已经描述了许多实施方案。然而,应当理解,可以进行各种修改。因此,其它实施方案在所附权利要求书的范围内。
序列表
<110> 伊卢米纳剑桥有限公司
KELLINGER, MATTHEW
BOUTELL, JONATHAN
<120> 重组酶突变体
<130> IP-1264-PRV
<160> 35
<170> PatentIn version 3.5
<210> 1
<211> 356
<212> PRT
<213> 肠杆菌噬菌体RB49
<400> 1
Met Ser Val Leu Glu Lys Leu Lys Lys Asn Ser Thr Leu Lys Thr Thr
1 5 10 15
Ala Val Leu Ser Lys Ser Ser Phe Phe Asn Glu Lys Thr Asn Thr Arg
20 25 30
Thr Lys Ile Pro Met Leu Asn Ile Ala Phe Ser Gly Asp Leu Lys Lys
35 40 45
Gly Phe Gln Ser Gly Leu Ile Phe Phe Ala Gly Pro Ser Lys His Phe
50 55 60
Lys Ser Asn Met Gly Leu Thr Cys Val Ser Ala Tyr Met Lys Gln Asn
65 70 75 80
Pro Asp Ala Ala Cys Leu Phe Phe Asp Ser Glu Phe Gly Ile Thr Ser
85 90 95
Ala Tyr Leu Glu Ser Met Gly Val Asp Pro Asp Arg Val Val His Val
100 105 110
Pro Ile Lys Asn Ile Glu Glu Leu Lys Phe Glu Ile Met Asn Gln Leu
115 120 125
Glu Gln Ile Thr Arg Glu Asp Lys Val Ile Ile Phe Ile Asp Ser Ile
130 135 140
Gly Asn Leu Ala Ser Lys Lys Glu Val Glu Asp Ala Ile Asn Glu Lys
145 150 155 160
Ser Ala Gln Asp Met Thr Arg Ala Lys Ala Leu Lys Gly Leu Phe Arg
165 170 175
Met Val Thr Pro Tyr Leu Thr Met Asn Asp Ile Pro Cys Ile Ala Ile
180 185 190
Asn His Thr Tyr Glu Thr Gln Glu Met Phe Ser Lys Thr Val Met Ser
195 200 205
Gly Gly Thr Gly Ala Met Tyr Ser Ala Asn Glu Val Phe Ile Ile Gly
210 215 220
Arg Arg Gln Gln Lys Glu Gly Thr Glu Ile Thr Gly Tyr Asp Phe Ile
225 230 235 240
Leu Asn Ala Glu Lys Ser Arg Thr Val Lys Glu Lys Ser Lys Phe Pro
245 250 255
Ile Ser Val Thr Phe Ser Gly Gly Ile Asp Pro Tyr Ser Gly Leu Leu
260 265 270
Glu Leu Ala Val Glu Leu Gly Trp Val Val Lys Pro Ser Asn Gly Trp
275 280 285
Tyr Ser Arg Ser Ile Leu Asn Thr Glu Thr Gly Glu Met Glu Thr Glu
290 295 300
Glu Arg Lys Phe Arg Ala Lys Glu Thr Asn Ser Ile Glu Phe Trp Lys
305 310 315 320
Pro Leu Leu Thr Asn Asp Lys Phe Asn Glu Ala Ile Asn Asp His Tyr
325 330 335
Lys Leu Gly Gln Val Ile Ser Asp Glu Ala Val Asp Lys Glu Ile Glu
340 345 350
Asp Met Leu Ala
355
<210> 2
<211> 356
<212> PRT
<213> 肠杆菌噬菌体RB49
<400> 2
Met Ser Val Leu Glu Lys Leu Lys Lys Asn Ser Thr Leu Lys Thr Thr
1 5 10 15
Ala Val Leu Ser Lys Ser Ser Phe Phe Asn Glu Lys Thr Asn Thr Arg
20 25 30
Thr Lys Ile Pro Met Leu Asn Ile Ala Phe Ser Gly Asp Leu Lys Lys
35 40 45
Gly Phe Gln Ser Gly Leu Ile Phe Phe Ala Gly Pro Ser Lys Ser Phe
50 55 60
Lys Ser Asn Met Gly Leu Thr Cys Val Ser Ala Tyr Met Lys Gln Asn
65 70 75 80
Pro Asp Ala Ala Cys Leu Phe Phe Asp Ser Glu Phe Gly Ile Thr Ser
85 90 95
Ala Tyr Leu Glu Ser Met Gly Val Asp Pro Asp Arg Val Val His Val
100 105 110
Pro Ile Lys Asn Ile Glu Glu Leu Lys Phe Glu Ile Met Asn Gln Leu
115 120 125
Glu Gln Ile Thr Arg Glu Asp Lys Val Ile Ile Phe Ile Asp Ser Ile
130 135 140
Gly Asn Leu Ala Ser Lys Lys Glu Val Glu Asp Ala Ile Asn Glu Lys
145 150 155 160
Ser Ala Gln Asp Met Thr Arg Ala Lys Ala Leu Lys Gly Leu Phe Arg
165 170 175
Met Val Thr Pro Tyr Leu Thr Met Asn Asp Ile Pro Cys Ile Ala Ile
180 185 190
Asn His Thr Tyr Glu Thr Gln Glu Met Phe Ser Lys Thr Val Met Ser
195 200 205
Gly Gly Thr Gly Ala Met Tyr Ser Ala Asn Glu Val Phe Ile Ile Gly
210 215 220
Arg Arg Gln Gln Lys Glu Gly Thr Glu Ile Thr Gly Tyr Asp Phe Ile
225 230 235 240
Leu Asn Ala Glu Lys Ser Arg Thr Val Lys Glu Lys Ser Lys Phe Lys
245 250 255
Ile Ser Val Thr Phe Ser Gly Gly Ile Asp Pro Tyr Ser Gly Leu Leu
260 265 270
Glu Leu Ala Val Glu Leu Gly Trp Val Val Lys Pro Ser Asn Gly Trp
275 280 285
Tyr Ser Arg Ser Ile Leu Asn Thr Glu Thr Gly Glu Met Glu Thr Glu
290 295 300
Glu Arg Lys Phe Arg Ala Lys Glu Thr Asn Ser Ile Glu Phe Trp Lys
305 310 315 320
Pro Leu Leu Thr Asn Asp Lys Phe Asn Glu Ala Ile Asn Asp His Tyr
325 330 335
Lys Leu Gly Gln Val Ile Ser Asp Glu Ala Val Asp Lys Glu Ile Glu
340 345 350
Asp Met Leu Ala
355
<210> 3
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 半保守域
<400> 3
Lys Glu Lys Ser Lys Phe Phe Ile
1 5
<210> 4
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 半保守域
<400> 4
Lys Glu Lys Ser Lys Phe Pro Ile
1 5
<210> 5
<211> 8
<212> PRT
<213> 人工序列
<220>
<223> 半保守域
<220>
<221> 变体
<222> (5)..(5)
<223> X = 任何AA
<220>
<221> 变体
<222> (7)..(7)
<223> X = 任何AA
<400> 5
Lys Glu Lys Ser Xaa Phe Xaa Ile
1 5
<210> 6
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 半保守域
<220>
<221> 变体
<222> (4)..(4)
<223> X = 任何AA
<220>
<221> 变体
<222> (5)..(5)
<223> X = 任何AA
<220>
<221> 变体
<222> (8)..(8)
<223> X = 任何AA
<220>
<221> 变体
<222> (9)..(9)
<223> X = 任何AA
<220>
<221> 变体
<222> (10)..(10)
<223> X = 任何AA
<220>
<221> 变体
<222> (11)..(11)
<223> X = 任何AA
<220>
<221> 变体
<222> (12)..(12)
<223> X = 任何AA
<220>
<221> 变体
<222> (13)..(13)
<223> X = 任何AA
<400> 6
Lys Ser Arg Xaa Xaa Lys Glu Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10
<210> 7
<211> 13
<212> PRT
<213> 人工序列
<220>
<223> 半保守域
<400> 7
Lys Ser Arg Thr Val Lys Glu Lys Ser Lys Phe Phe Ile
1 5 10
<210> 8
<211> 391
<212> PRT
<213> 肠杆菌噬菌体T4
<400> 8
Met Ser Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser Lys Leu
1 5 10 15
Thr Ala Glu Leu Thr Ala Ser Lys Phe Phe Asn Glu Lys Asp Val Val
20 25 30
Arg Thr Lys Ile Pro Met Met Asn Ile Ala Leu Ser Gly Glu Ile Thr
35 40 45
Gly Gly Met Gln Ser Gly Leu Leu Ile Leu Ala Gly Pro Ser Lys Ser
50 55 60
Phe Lys Ser Asn Phe Gly Leu Thr Met Val Ser Ser Tyr Met Arg Gln
65 70 75 80
Tyr Pro Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Phe Gly Ile Thr
85 90 95
Pro Ala Tyr Leu Arg Ser Met Gly Val Asp Pro Glu Arg Val Ile His
100 105 110
Thr Pro Val Gln Ser Leu Glu Gln Leu Arg Ile Asp Met Val Asn Gln
115 120 125
Leu Asp Ala Ile Glu Arg Gly Glu Lys Val Val Val Phe Ile Asp Ser
130 135 140
Leu Gly Asn Leu Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu Asn Glu
145 150 155 160
Lys Val Val Ser Asp Met Thr Arg Ala Lys Thr Met Lys Ser Leu Phe
165 170 175
Arg Ile Val Thr Pro Tyr Phe Ser Thr Lys Asn Ile Pro Cys Ile Ala
180 185 190
Ile Asn His Thr Tyr Glu Thr Gln Glu Met Phe Ser Lys Thr Val Met
195 200 205
Gly Gly Gly Thr Gly Pro Met Tyr Ser Ala Asp Thr Val Phe Ile Ile
210 215 220
Gly Lys Arg Gln Ile Lys Asp Gly Ser Asp Leu Gln Gly Tyr Gln Phe
225 230 235 240
Val Leu Asn Val Glu Lys Ser Arg Thr Val Lys Glu Lys Ser Lys Phe
245 250 255
Phe Ile Asp Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser Gly Leu
260 265 270
Leu Asp Met Ala Leu Glu Leu Gly Phe Val Val Lys Pro Lys Asn Gly
275 280 285
Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met Ile Arg
290 295 300
Glu Glu Lys Ser Trp Arg Ala Lys Asp Thr Asn Cys Thr Thr Phe Trp
305 310 315 320
Gly Pro Leu Phe Lys His Gln Pro Phe Arg Asp Ala Ile Lys Arg Ala
325 330 335
Tyr Gln Leu Gly Ala Ile Asp Ser Asn Glu Ile Val Glu Ala Glu Val
340 345 350
Asp Glu Leu Ile Asn Ser Lys Val Glu Lys Phe Lys Ser Pro Glu Ser
355 360 365
Lys Ser Lys Ser Ala Ala Asp Leu Glu Thr Asp Leu Glu Gln Leu Ser
370 375 380
Asp Met Glu Glu Phe Asn Glu
385 390
<210> 9
<211> 393
<212> PRT
<213> 肠杆菌噬菌体T6
<400> 9
Met Ser Ile Ala Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser
1 5 10 15
Lys Met Thr Ala Glu Leu Thr Thr Ser Lys Phe Phe Asn Glu Lys Asp
20 25 30
Val Ile Arg Thr Lys Ile Pro Met Leu Asn Ile Ala Ile Ser Gly Ala
35 40 45
Ile Asp Gly Gly Met Gln Ser Gly Leu Thr Ile Phe Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Met Ser Leu Thr Met Val Ala Ala Tyr Leu
65 70 75 80
Asn Lys Tyr Pro Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Phe Gly
85 90 95
Ile Thr Pro Ala Tyr Leu Arg Ser Met Gly Val Asp Pro Glu Arg Val
100 105 110
Ile His Thr Pro Ile Gln Ser Val Glu Gln Leu Lys Ile Asp Met Val
115 120 125
Asn Gln Leu Glu Ala Ile Glu Arg Gly Glu Lys Val Ile Val Phe Ile
130 135 140
Asp Ser Ile Gly Asn Met Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu
145 150 155 160
Asn Glu Lys Ser Val Ala Asp Met Thr Arg Ala Lys Ser Leu Lys Ser
165 170 175
Leu Phe Arg Ile Val Thr Pro Tyr Phe Ser Ile Lys Asn Ile Pro Cys
180 185 190
Val Ala Val Asn His Thr Ile Glu Thr Ile Glu Met Phe Ser Lys Thr
195 200 205
Val Met Thr Gly Gly Thr Gly Val Met Tyr Ser Ala Asp Thr Val Phe
210 215 220
Ile Ile Gly Lys Arg Gln Ile Lys Asp Gly Ser Asp Leu Gln Gly Tyr
225 230 235 240
Gln Phe Val Leu Asn Val Glu Lys Ser Arg Thr Val Lys Glu Lys Ser
245 250 255
Lys Phe Phe Ile Asp Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser
260 265 270
Gly Leu Leu Asp Met Ala Leu Glu Leu Gly Phe Val Val Lys Pro Lys
275 280 285
Asn Gly Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met
290 295 300
Ile Arg Glu Glu Lys Ser Trp Arg Ala Lys Asp Thr Asn Cys Thr Thr
305 310 315 320
Phe Trp Gly Pro Leu Phe Lys His Gln Pro Phe Arg Asp Ala Ile Lys
325 330 335
Arg Ala Tyr Gln Leu Gly Ala Ile Asp Ser Asn Glu Ile Val Glu Ala
340 345 350
Glu Val Asp Glu Leu Ile Asn Ser Lys Val Glu Lys Phe Lys Ser Pro
355 360 365
Glu Ser Lys Ser Lys Ser Ala Ala Asp Leu Glu Thr Asp Leu Glu Gln
370 375 380
Leu Ser Asp Met Glu Glu Phe Asn Glu
385 390
<210> 10
<211> 387
<212> PRT
<213> 不动杆菌噬菌体133
<400> 10
Met Ser Ser Leu Lys Glu Arg Leu Ile Lys Ala Ser Thr Ser Lys Met
1 5 10 15
Thr Ala Glu Leu Thr Lys Ser Lys Phe Phe Asn Asp Lys Thr Val Val
20 25 30
Arg Thr Arg Ile Pro Met Leu Asn Ile Ala Ile Ser Gly Ala Leu Asn
35 40 45
Gly Gly Met Gln Ser Gly Leu Thr Ile Phe Ala Gly Pro Ser Lys His
50 55 60
Phe Lys Ser Asn Met Gly Leu Thr Met Val Ala Ala Tyr Met Lys Ala
65 70 75 80
Phe Pro Asp Ala Val Cys Met Phe Tyr Asp Ser Glu Phe Gly Ile Thr
85 90 95
Pro Ala Tyr Leu Lys Ala Met Gly Val Asp Pro Asp Arg Val Ile His
100 105 110
Thr Pro Val Gln Ser Val Glu Gln Leu Lys Ile Asp Met Thr Asn Gln
115 120 125
Leu Glu Glu Val Lys Arg Gly Glu Lys Val Ile Val Phe Ile Asp Ser
130 135 140
Ile Gly Asn Leu Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu Asn Glu
145 150 155 160
Lys Thr Thr Ala Asp Met Thr Arg Ala Lys Ala Leu Lys Ser Leu Phe
165 170 175
Arg Ile Val Thr Pro Tyr Phe Ser Ile Lys Asp Ile Pro Cys Val Ala
180 185 190
Val Asn His Thr Leu Gln Thr Leu Glu Met Phe Ser Lys Glu Val Met
195 200 205
Thr Gly Gly Thr Gly Val Met Tyr Ser Ala Asp Thr Val Phe Phe Ile
210 215 220
Gly Lys Arg Gln Val Lys Asp Gly Thr Glu Leu Ala Gly Tyr Glu Phe
225 230 235 240
Ile Leu Lys Ala Glu Lys Ser Arg Met Val Lys Glu Lys Ser Val Phe
245 250 255
Pro Ile Thr Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser Gly Leu
260 265 270
Leu Glu Met Ala Thr Asp Leu Gly Phe Val Val Lys Pro Lys Val Gly
275 280 285
Trp Tyr Lys Arg Ala Met Met Val Asp Gly Val Met Gln His Glu Glu
290 295 300
Lys Ser Trp Arg Ala Lys Asp Thr Asp Ser Ile Asp Phe Trp Gly Pro
305 310 315 320
Leu Phe Lys His Asp Glu Phe Arg Lys Ala Ile Glu Thr Arg Tyr Gln
325 330 335
Leu Gly Ser Ile Glu Ser Asp Ala Glu Val Asp Ala Glu Val Asp Ala
340 345 350
Leu Ile Gly Ser Lys Thr Thr Ala Lys Ile Ser Gly Val Asn Phe Gly
355 360 365
Pro Ala Glu Ser Ala Ala Asp Lys Glu Gln Gln Leu Glu Asp Phe Val
370 375 380
Asp Glu Asp
385
<210> 11
<211> 390
<212> PRT
<213> 肠杆菌噬菌体RB69
<400> 11
Met Ser Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser Lys Met
1 5 10 15
Thr Ala Asp Leu Thr Lys Ser Lys Leu Phe Asn Asn Arg Asp Glu Val
20 25 30
Pro Thr Arg Ile Pro Met Leu Asn Ile Ala Leu Gly Gly Ala Leu Asn
35 40 45
Ala Gly Leu Gln Ser Gly Leu Thr Ile Phe Ala Ala Pro Ser Lys His
50 55 60
Phe Lys Thr Leu Phe Gly Leu Thr Met Val Ala Ala Tyr Met Lys Lys
65 70 75 80
Tyr Lys Asp Ala Ile Cys Leu Phe Tyr Asp Ser Glu Phe Gly Ala Ser
85 90 95
Glu Ser Tyr Phe Arg Ser Met Gly Val Asp Leu Asp Arg Val Val His
100 105 110
Thr Pro Ile Gln Ser Val Glu Gln Leu Lys Val Asp Met Thr Asn Gln
115 120 125
Leu Asp Ala Ile Glu Arg Gly Asp Lys Val Ile Ile Phe Ile Asp Ser
130 135 140
Ile Gly Asn Thr Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu Asn Glu
145 150 155 160
Lys Val Val Gly Asp Met Ser Arg Ala Lys Ala Leu Lys Ser Leu Phe
165 170 175
Arg Ile Val Thr Pro Tyr Leu Thr Ile Lys Asp Ile Pro Cys Val Ala
180 185 190
Ile Asn His Thr Ala Met Glu Ile Gly Gly Leu Tyr Pro Lys Glu Ile
195 200 205
Met Gly Gly Gly Thr Gly Ile Leu Tyr Ser Ala Asn Thr Val Phe Phe
210 215 220
Ile Ser Lys Arg Gln Val Lys Glu Gly Thr Glu Leu Thr Gly Tyr Asp
225 230 235 240
Phe Thr Leu Lys Ala Glu Lys Ser Arg Thr Val Lys Glu Lys Ser Thr
245 250 255
Phe Pro Ile Thr Val Asn Phe Asp Gly Gly Ile Asp Pro Phe Ser Gly
260 265 270
Leu Leu Glu Met Ala Thr Glu Ile Gly Phe Val Val Lys Pro Lys Ala
275 280 285
Gly Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met Ile
290 295 300
Arg Glu Glu Lys Ser Trp Arg Ala Lys Ala Thr Asp Cys Val Glu Phe
305 310 315 320
Trp Gly Pro Leu Phe Lys His Lys Pro Phe Arg Asp Ala Ile Glu Thr
325 330 335
Lys Tyr Lys Leu Gly Ala Ile Ser Ser Ile Lys Glu Val Asp Asp Ala
340 345 350
Val Asn Asp Leu Ile Asn Cys Lys Ala Thr Thr Lys Val Pro Val Lys
355 360 365
Thr Ser Asp Ala Pro Ser Ala Ala Asp Ile Glu Asn Asp Leu Asp Glu
370 375 380
Met Glu Asp Phe Asp Glu
385 390
<210> 12
<211> 411
<212> PRT
<213> 气单胞菌噬菌体Aeh1
<400> 12
Met Ala Lys Gly Ile Lys Thr Ala Lys Thr Gly Asn Leu Gly Ser Leu
1 5 10 15
Met Ser Lys Leu Ala Gly Thr Ser Ser Asn Lys Met Ser Ser Val Leu
20 25 30
Ala Asp Ser Lys Phe Phe Asn Asp Lys Asp Cys Val Arg Thr Arg Val
35 40 45
Pro Leu Leu Asn Leu Ala Met Ser Gly Glu Leu Asp Gly Gly Leu Thr
50 55 60
Pro Gly Leu Thr Val Leu Ala Gly Pro Ser Lys His Phe Lys Ser Asn
65 70 75 80
Leu Ser Leu Val Phe Val Ala Ala Tyr Leu Arg Lys Tyr Pro Asp Ala
85 90 95
Val Cys Ile Phe Phe Asp Asn Glu Phe Gly Ser Thr Pro Gly Tyr Phe
100 105 110
Glu Ser Gln Gly Val Asp Ile Ser Arg Val Ile His Cys Pro Phe Lys
115 120 125
Asn Ile Glu Glu Leu Lys Phe Asp Ile Val Lys Lys Leu Glu Ala Ile
130 135 140
Glu Arg Gly Asp Arg Val Ile Val Phe Val Asp Ser Ile Gly Asn Ala
145 150 155 160
Ala Ser Lys Lys Glu Ile Asp Asp Ala Ile Asp Glu Lys Ser Val Ser
165 170 175
Asp Met Thr Arg Ala Lys Gln Ile Lys Ser Leu Thr Arg Met Met Thr
180 185 190
Pro Tyr Leu Thr Val Asn Asp Ile Pro Ala Ile Met Val Ala His Thr
195 200 205
Tyr Asp Thr Gln Glu Met Tyr Ser Lys Lys Val Val Ser Gly Gly Thr
210 215 220
Gly Ile Thr Tyr Ser Ser Asp Thr Val Ile Ile Ile Gly Arg Gln Gln
225 230 235 240
Glu Lys Asp Gly Lys Glu Leu Leu Gly Tyr Asn Phe Val Leu Asn Met
245 250 255
Glu Lys Ser Arg Phe Val Lys Glu Gln Ser Lys Leu Pro Leu Glu Val
260 265 270
Thr Phe Gln Gly Gly Ile Asn Thr Tyr Ser Gly Met Leu Asp Ile Ala
275 280 285
Leu Glu Val Gly Phe Val Val Lys Pro Ser Asn Gly Trp Phe Ser Arg
290 295 300
Ala Phe Leu Asp Glu Glu Thr Gly Glu Leu Val Glu Glu Asp Arg Lys
305 310 315 320
Trp Arg Arg Ala Asp Thr Asn Cys Leu Glu Phe Trp Lys Pro Met Phe
325 330 335
Ala His Gln Pro Phe Lys Thr Ala Cys Ser Asp Met Phe Lys Leu Lys
340 345 350
Ser Val Ala Val Lys Asp Glu Val Phe Asp Glu Val Asp Glu Leu Phe
355 360 365
Ser Gly Glu Ala Glu Met Pro Val Asn Met Gly Arg Lys Leu Asp Thr
370 375 380
Ala Asp Gln Glu Glu Ile Asp Gln Leu Glu Glu Val Asp Val Glu Gly
385 390 395 400
Ser Asp Ser Asp Glu Leu Phe Ala Asn Leu Asp
405 410
<210> 13
<211> 368
<212> PRT
<213> 气单胞菌噬菌体65
<400> 13
Met Ala Lys Lys Ala Lys Val Val Asn Ser Gly Asp Leu Leu Glu Arg
1 5 10 15
Leu Asn Gly Thr Ser Ser Asn Lys Met Ser Ala Met Leu Ala Glu Ser
20 25 30
Ile Phe Phe Asn Glu Lys Asp Thr Ile Arg Thr Arg Val Pro Ile Ile
35 40 45
Asn Leu Met Met Ser Gly Arg Leu Asp Gly Gly Ile Thr Pro Gly Leu
50 55 60
Thr Cys Ile Ala Gly Pro Ser Lys His Phe Lys Ser Asn Leu Ser Leu
65 70 75 80
Val Met Val Ser Ala Tyr Leu Arg Lys Tyr Pro Lys Ala Val Cys Leu
85 90 95
Phe Phe Asp Asn Glu Phe Gly Ser Thr Pro Asp Tyr Phe Thr Ser Gln
100 105 110
Gly Val Asp Ile Ser Arg Val Val His Cys Pro Phe Ile Asp Val Glu
115 120 125
Glu Leu Lys Phe Asp Ile Val Lys Lys Leu Glu Ser Ile Thr Arg Gly
130 135 140
Asp Lys Val Ile Ile Tyr Ile Asp Ser Ile Gly Asn Val Ala Ser Lys
145 150 155 160
Lys Glu Leu Gln Asp Ala Lys Asp Glu Lys Ser Ala Gln Asp Met Thr
165 170 175
Arg Ala Lys Gln Ile Lys Ser Leu Phe Arg Met Val Thr Pro Tyr Leu
180 185 190
Thr Val Leu Asp Ile Pro Cys Ile Ala Val Asn His Thr Tyr Glu Thr
195 200 205
Gln Glu Met Phe Ser Lys Thr Val Met Ser Gly Gly Thr Gly Pro Met
210 215 220
Tyr Ser Ala Asp Thr Val Ile Ile Leu Gly Lys Gln Gln Asp Lys Asp
225 230 235 240
Gly Lys Glu Leu Leu Gly Tyr Asn Phe Val Met Asn Ala Glu Lys Ser
245 250 255
Arg Ala Ile Lys Glu Lys Ser Lys Leu Asp Leu Met Val Ser Phe Glu
260 265 270
Gly Gly Ile Asn Thr Tyr Ser Gly Leu Leu Lys Ile Ala Gln Glu Leu
275 280 285
Gly Phe Val Thr Lys Pro Gln Asn Ala Arg Tyr Gln Arg Asn Phe Leu
290 295 300
Asp Leu Glu Pro Gly Glu Met Val Ile Pro Glu Asp Glu Lys Lys Trp
305 310 315 320
Thr Glu Glu Glu Ser Asp Ser Leu Glu Phe Trp Lys Pro Met Phe Ser
325 330 335
His Lys Pro Phe Met Asp Ala Val Ser Asn Ala Tyr Lys Leu Lys Ala
340 345 350
Val Glu Val Ser Gln Glu Val Phe Asp Glu Val Asp Gln Leu Phe Gly
355 360 365
<210> 14
<211> 366
<212> PRT
<213> 弧菌噬菌体KVP40
<400> 14
Met Ser Asp Leu Met Lys Ser Leu Lys Lys Ser Ser Thr Ser Gly Tyr
1 5 10 15
Ala Gln Val Leu Ser Glu Ser Gln Phe Met Phe Asp Lys Asp His Thr
20 25 30
Arg Thr Tyr Val Pro Ala Ile Asn Ile Ala Phe Ser Gly Glu Val Asp
35 40 45
Gly Gly Leu Thr Ser Gly Leu Thr Val Leu Ala Gly Pro Ser Lys His
50 55 60
Phe Lys Ser Asn Leu Gly Leu Val Gly Val Ala Ala Tyr Leu Lys Lys
65 70 75 80
Tyr Pro Asp Ala Val Cys Val Phe Ile Asp Thr Glu Phe Gly Ile Thr
85 90 95
Pro Ser Tyr Leu Arg Ser Gln Gly Val Asp Pro Asp Arg Val Leu His
100 105 110
Ile Gln Cys Glu Ser Val Glu Arg Met Lys Phe Glu Met Ala Asn Gln
115 120 125
Leu Lys Asp Leu Ala Glu Arg Lys Arg Ala Lys Lys Ala Gly Glu Glu
130 135 140
Pro Asp Arg Val Ile Phe Phe Ile Asp Ser Val Gly Asn Val Ala Ser
145 150 155 160
Ala Lys Glu Ile Asp Asp Ala Gln Asn Glu Lys Ser Val Ala Asp Met
165 170 175
Ser Arg Ala Lys Gln Leu Lys Ser Leu Phe Arg Ile Ile Thr Pro Tyr
180 185 190
Phe Thr Met Leu Asp Ile Pro Cys Ile Ala Ile Asn His Thr Tyr Gln
195 200 205
Thr Gln Glu Ile Tyr Ser Lys Thr Val Met Ser Gly Gly Thr Gly Ile
210 215 220
Met Tyr Ser Ala Asp Thr Val Ile Ile Leu Gly Lys Gln Gln Glu Lys
225 230 235 240
Asp Gly Lys Asp Ile Ile Gly Tyr His Phe Ile Met Asn Ile Glu Lys
245 250 255
Ser Arg Phe Val Lys Glu Lys Met Lys Val Pro Leu Thr Val Thr Tyr
260 265 270
Glu Asn Gly Ile Asp Pro Phe Ser Gly Leu Leu Asp Ile Ala Leu Gln
275 280 285
Thr Gly His Val Val Lys Pro Ser Asn Gly Trp Tyr Gln Arg Ala Thr
290 295 300
Val Asp Glu Glu Thr Gly Glu Met Ile Val Glu Glu Lys Lys Tyr Arg
305 310 315 320
Ala Lys Glu Thr Gln Thr Ile Ser Phe Trp Lys Asp Ile Ile Asn Ser
325 330 335
Pro Thr Phe Lys Glu Gly Val Lys Arg Ile Tyr Cys Leu Gly Gln Leu
340 345 350
Asp Glu Ser Glu Leu Phe Gly Glu Val Asp Ser Leu Phe Asp
355 360 365
<210> 15
<211> 386
<212> PRT
<213> 肠杆菌噬菌体RB43
<400> 15
Met Ser Asn Lys Ala Leu Leu Lys Lys Leu Ile Lys Asn Ser Asn Ser
1 5 10 15
Gln Ser Ala Ala Ile Leu Ser Glu Ser Asp Val Phe Asn Asn Ile Thr
20 25 30
Lys Thr Arg Thr Arg Val Pro Ile Leu Asn Leu Ala Leu Ser Gly Ala
35 40 45
Phe Asp Gly Gly Leu Thr Ser Gly Leu Thr Leu Phe Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Leu Gly Leu Val Thr Val Ser Ala Tyr Leu
65 70 75 80
Lys Ala Asn Glu Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Lys Gly
85 90 95
Val Thr Lys Ser Tyr Leu Lys Ser Met Gly Val Asp Pro Asp Arg Val
100 105 110
Val Tyr Thr Arg Ile Thr Thr Val Glu Gln Leu Arg Asn Asp Val Val
115 120 125
Ser Gln Leu Asp Ala Leu Glu Arg Gly Asp Lys Val Ile Ile Phe Val
130 135 140
Asp Ser Val Gly Asn Thr Ala Ser Lys Lys Glu Leu Ala Asp Ala Leu
145 150 155 160
Ser Asp Asn Asp Lys Gln Asp Met Thr Arg Ala Lys Ala Leu Lys Gly
165 170 175
Met Phe Arg Met Val Thr Pro Tyr Leu Ala Asp Leu Asp Ile Pro Met
180 185 190
Val Cys Ile Cys His Thr Tyr Asp Thr Gln Glu Met Tyr Ser Lys Lys
195 200 205
Val Ile Ser Gly Gly Thr Gly Leu Met Tyr Ser Ala Asp Thr Ala Ile
210 215 220
Ile Leu Gly Lys Gln Gln Val Lys Glu Gly Thr Glu Val Val Gly Tyr
225 230 235 240
Asp Phe Ile Met Asn Ile Glu Lys Ser Arg Phe Val Lys Glu Lys Ser
245 250 255
Lys Phe Pro Leu His Val Thr Tyr Glu Gly Gly Ile Ser Met Tyr Ser
260 265 270
Gly Leu Leu Asp Leu Ala Met Glu Met Asn Phe Val Gln Thr Pro Thr
275 280 285
Lys Gly Trp Arg Gly Arg Ala Phe Leu Asn Thr Glu Thr Gly Glu Leu
290 295 300
Glu Leu Glu Glu Lys Lys Trp Arg Glu Ser Glu Thr Asn Ser Ile Glu
305 310 315 320
Phe Trp Arg Pro Leu Phe Thr His Gln Pro Phe Leu Asp Ala Ile Gln
325 330 335
Asp Lys Tyr Arg Ile Pro Asp Lys Glu Ile Thr Asp Gly Ala Ala Leu
340 345 350
Glu Asp Leu Tyr Ser Thr Asp Glu Pro Glu Ser Asn Lys Ile Asp Leu
355 360 365
Asp Asp Asp Ile Pro Asp Asp Ile Gly Ile Asp Gln Asp Glu Glu Pro
370 375 380
Ile Met
385
<210> 16
<211> 335
<212> PRT
<213> 原绿球藻噬菌体P-SSM2
<400> 16
Met Asp Phe Leu Lys Glu Ile Val Lys Glu Ile Gly Asp Glu Tyr Thr
1 5 10 15
Gln Val Ala Ala Asp Ile Gln Glu Asn Glu Arg Phe Ile Asp Thr Gly
20 25 30
Ser Tyr Ile Phe Asn Gly Leu Val Ser Gly Ser Ile Phe Gly Gly Val
35 40 45
Ser Ser Ser Arg Ile Thr Ala Ile Ala Gly Glu Ser Ser Thr Gly Lys
50 55 60
Thr Tyr Phe Ser Leu Ala Val Val Lys Asn Phe Leu Asp Asn Asn Pro
65 70 75 80
Asp Gly Tyr Cys Leu Tyr Phe Asp Thr Glu Ala Ala Val Asn Lys Gly
85 90 95
Leu Leu Glu Ser Arg Gly Ile Asp Met Asn Arg Leu Val Val Val Asn
100 105 110
Val Val Thr Ile Glu Glu Phe Arg Ser Lys Ala Leu Arg Ala Val Asp
115 120 125
Ile Tyr Leu Lys Thr Ser Glu Glu Glu Arg Lys Pro Cys Met Phe Val
130 135 140
Leu Asp Ser Leu Gly Met Leu Ser Thr Glu Lys Glu Ile Arg Asp Ala
145 150 155 160
Leu Asp Asp Lys Gln Val Arg Asp Met Thr Lys Ser Gln Leu Val Lys
165 170 175
Gly Ala Phe Arg Met Leu Thr Leu Lys Leu Gly Gln Ala Asn Ile Pro
180 185 190
Leu Ile Val Thr Asn His Thr Tyr Asp Val Ile Gly Ser Tyr Val Pro
195 200 205
Thr Lys Glu Met Gly Gly Gly Ser Gly Leu Lys Tyr Ala Ala Ser Thr
210 215 220
Ile Ile Tyr Leu Ser Lys Lys Lys Glu Lys Asp Gln Lys Glu Val Ile
225 230 235 240
Gly Asn Leu Ile Lys Ala Lys Thr His Lys Ser Arg Leu Ser Lys Glu
245 250 255
Asn Lys Glu Val Gln Ile Arg Leu Tyr Tyr Asp Glu Arg Gly Leu Asp
260 265 270
Arg Tyr Tyr Gly Leu Leu Glu Leu Gly Glu Ile Gly Gly Met Trp Lys
275 280 285
Asn Val Ala Gly Arg Tyr Glu Met Asn Gly Lys Lys Ile Tyr Ala Lys
290 295 300
Glu Ile Leu Lys Asn Pro Thr Glu Tyr Phe Thr Asp Asp Ile Met Glu
305 310 315 320
Gln Leu Asp Asn Ile Ala Lys Glu His Phe Ser Tyr Gly Thr Asn
325 330 335
<210> 17
<211> 336
<212> PRT
<213> 原绿球藻噬菌体P-SSM4
<400> 17
Met Asn Phe Leu Lys Asp Ile Ala Lys Glu Ile Gly Asn Asp Tyr Ala
1 5 10 15
Ser Leu Val Ser Glu Gly Val Ser Ala Gly Asp Thr Ala Gly Phe Ile
20 25 30
Asp Thr Gly Ser Tyr Ile Phe Asn Ala Leu Leu Ser Gly Ser Ile Tyr
35 40 45
Gly Gly Ile Pro Asn Asn Lys Ile Thr Ala Ile Ala Gly Glu Thr Ser
50 55 60
Thr Gly Lys Thr Phe Phe Cys Leu Gly Met Val Gln His Phe Leu Glu
65 70 75 80
Ser Asn Pro Asp Ala Gly Val Ile Tyr Phe Glu Ser Glu Ser Ala Ile
85 90 95
Ser Lys Gln Met Ile Glu Asp Arg Gly Ile Asp Ser Asn Arg Met Leu
100 105 110
Leu Val Pro Val Thr Thr Val Gln Glu Phe Arg Leu Gln Ala Ile Lys
115 120 125
Ile Leu Asp Lys Tyr Asn Glu Gln Thr Ala Glu Glu Arg Lys Pro Leu
130 135 140
Met Phe Val Leu Asp Ser Leu Gly Met Leu Ser Thr Ser Lys Glu Val
145 150 155 160
Glu Asp Ser Glu Ala Gly Lys Glu Thr Arg Asp Met Thr Arg Ala Gln
165 170 175
Val Val Lys Ser Ile Phe Arg Val Leu Thr Leu Lys Leu Gly Lys Ala
180 185 190
Asn Val Pro Leu Ile Val Thr Asn His Thr Tyr Asp Val Val Gly Ala
195 200 205
Tyr Ile Pro Thr Lys Glu Met Gly Gly Gly Ser Gly Leu Lys Tyr Ala
210 215 220
Ala Ser Thr Ile Val Tyr Leu Ser Lys Lys Lys Glu Lys Asn Gly Lys
225 230 235 240
Glu Val Val Gly Asn Ile Ile Lys Cys Lys Thr Ala Lys Ser Arg Leu
245 250 255
Thr Lys Glu Asn Ser Asp Val Glu Thr Arg Leu Tyr Tyr Asp Arg Gly
260 265 270
Leu Asp Arg Tyr Tyr Gly Leu Leu Glu Leu Gly Glu Lys His Gly Val
275 280 285
Phe Ser Arg Lys Gly Asn Arg Val Val Val Gly Asp Ser Ser Val Tyr
290 295 300
Pro Ser Ala Ile Leu Ala Asp Pro Asp Lys Tyr Phe Thr Glu Glu Leu
305 310 315 320
Met Glu Lys Leu Asp Glu Ala Ala Ala Lys Glu Phe Arg Tyr Gly Asn
325 330 335
<210> 18
<211> 343
<212> PRT
<213> 聚球藻噬菌体S-PM2
<400> 18
Met Ser Phe Leu Asp Ser Val Ile Lys Asp Ser Lys Asn Glu Tyr Ala
1 5 10 15
Ala Phe Ala Ser Glu Gly Val Ala Ala Gly Asp Val Glu Ser Phe Val
20 25 30
Asp Thr Gly Ser Tyr Ile Phe Asn Ala Leu Val Ser Gly Ser Ile Phe
35 40 45
Gly Gly Ile Pro Ser Asn Lys Ile Thr Ala Leu Ala Gly Glu Ser Gly
50 55 60
Thr Gly Lys Thr Phe Phe Cys Leu Ser Val Val Arg Asn Phe Leu Asn
65 70 75 80
Thr Asp Pro Asp Ala Gly Val Ile Tyr Phe Glu Thr Glu Ser Ala Ile
85 90 95
Ser Lys Gln Met Ile Glu Ser Arg Gly Ile Asp Ser Thr Arg Met Ile
100 105 110
Ile Phe Pro Val Asp Thr Ile Glu Asp Phe Arg Thr Gln Ala Val Arg
115 120 125
Ile Ile Asp Lys Tyr Met Glu Gln Asn Lys Ser Glu Arg Lys Pro Leu
130 135 140
Met Phe Val Leu Asp Ser Leu Gly Met Leu Ala Thr Lys Lys Glu Val
145 150 155 160
Glu Asp Ala Ser Asn Asp Lys Gln Val Arg Asp Met Thr Lys Ala Gln
165 170 175
Ile Val Lys Ser Ala Phe Arg Ile Leu Thr Leu Lys Met Gly Lys Ala
180 185 190
Asn Ile Pro Met Leu Val Thr Asn His Thr Tyr Asp Val Val Gly Ser
195 200 205
Tyr Val Pro Thr Lys Glu Met Gly Gly Gly Ser Gly Leu Lys Tyr Ser
210 215 220
Ala Ser Thr Ile Val Tyr Leu Gly Lys Lys Lys Glu Lys Asp Gly Thr
225 230 235 240
Asp Leu Val Gly Asn Ile Ile Lys Cys Glu Ala Lys Lys Ser Arg Leu
245 250 255
Thr Arg Glu Gly Ser Lys Val Glu Thr Arg Leu Phe Phe Asp Gln Arg
260 265 270
Gly Leu Glu Arg Tyr Tyr Gly Met Leu Glu Leu Gly Glu Arg Ala Gly
275 280 285
Leu Trp Lys Asn Thr Ala Gly Arg Tyr Glu Ile Asn Gly Lys Lys Val
290 295 300
Tyr Gly Lys Gln Ile Leu Ala Asn Pro Asp Glu Phe Phe Thr Glu Glu
305 310 315 320
Ile Leu Gln Glu Leu Asp Lys Gln Ala Gln Arg Glu Phe Leu Tyr Gly
325 330 335
Ala Ser Asp Asp Gly Glu Asp
340
<210> 19
<211> 393
<212> PRT
<213> 肠杆菌噬菌体RB32
<400> 19
Met Ser Ile Ala Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser
1 5 10 15
Lys Met Thr Ala Glu Leu Thr Thr Ser Lys Phe Phe Asn Glu Lys Asp
20 25 30
Val Ile Arg Thr Lys Ile Pro Met Leu Asn Ile Ala Ile Ser Gly Ala
35 40 45
Ile Asp Gly Gly Met Gln Ser Gly Leu Thr Ile Phe Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Met Ser Leu Thr Met Val Ala Ala Tyr Leu
65 70 75 80
Asn Lys Tyr Pro Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Phe Gly
85 90 95
Ile Thr Pro Ala Tyr Leu Arg Ser Met Gly Val Asp Pro Glu Arg Val
100 105 110
Ile His Thr Pro Ile Gln Ser Val Glu Gln Leu Lys Ile Asp Met Val
115 120 125
Asn Gln Leu Glu Ala Ile Glu Arg Gly Glu Lys Val Ile Val Phe Ile
130 135 140
Asp Ser Ile Gly Asn Met Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu
145 150 155 160
Asn Glu Lys Ser Val Ala Asp Met Thr Arg Ala Lys Ser Leu Lys Ser
165 170 175
Leu Phe Arg Ile Val Thr Pro Tyr Phe Ser Ile Lys Asn Ile Pro Cys
180 185 190
Val Ala Val Asn His Thr Ile Glu Thr Ile Glu Met Phe Ser Lys Thr
195 200 205
Val Met Thr Gly Gly Thr Gly Val Met Tyr Ser Ala Asp Thr Val Phe
210 215 220
Ile Ile Gly Lys Arg Gln Ile Lys Asp Gly Ser Asp Leu Gln Gly Tyr
225 230 235 240
Gln Phe Val Leu Asn Val Glu Lys Ser Arg Thr Val Lys Glu Lys Ser
245 250 255
Lys Phe Phe Ile Asp Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser
260 265 270
Gly Leu Leu Asp Met Ala Leu Glu Leu Gly Phe Val Val Lys Pro Lys
275 280 285
Asn Gly Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met
290 295 300
Ile Arg Glu Glu Lys Ser Trp Arg Ala Lys Asp Thr Asn Cys Thr Thr
305 310 315 320
Phe Trp Gly Pro Leu Phe Lys His Gln Pro Phe Arg Asp Ala Ile Lys
325 330 335
Arg Ala Tyr Gln Leu Gly Ala Ile Asp Ser Asn Glu Ile Val Glu Ala
340 345 350
Glu Val Asp Glu Leu Ile Asn Ser Lys Val Glu Lys Phe Lys Ser Pro
355 360 365
Glu Ser Lys Ser Lys Ser Ala Ala Asp Leu Glu Thr Asp Leu Glu Gln
370 375 380
Leu Ser Asp Met Glu Glu Phe Asn Glu
385 390
<210> 20
<211> 366
<212> PRT
<213> 弧菌噬菌体nt-1
<400> 20
Met Ser Asp Leu Leu Lys Ser Leu Lys Lys Ser Ser Thr Ser Gly Tyr
1 5 10 15
Ala His Val Leu Ser Glu Ser Gln Phe Met Phe Glu Lys Asp His Thr
20 25 30
Arg Thr Tyr Val Pro Ala Ile Asn Ile Ala Phe Ser Gly Glu Val Asp
35 40 45
Gly Gly Leu Thr Ser Gly Leu Thr Val Leu Ala Gly Pro Ser Lys His
50 55 60
Phe Lys Ser Asn Leu Gly Leu Val Gly Val Ala Ala Tyr Leu Lys Lys
65 70 75 80
Tyr Pro Glu Ala Ile Cys Val Phe Ile Asp Thr Glu Phe Gly Ile Thr
85 90 95
Pro Ser Tyr Leu Lys Ser Gln Gly Val Asp Pro Glu Arg Val Leu His
100 105 110
Ile Gln Cys Glu Ser Val Glu Arg Met Lys Phe Glu Met Ala Asn Gln
115 120 125
Leu Lys Asp Leu Ala Glu Arg Lys Arg Ala Lys Lys Ala Gly Glu Glu
130 135 140
Pro Asp Arg Val Val Phe Phe Ile Asp Ser Val Gly Asn Val Ala Ser
145 150 155 160
Ala Lys Glu Ile Asp Asp Ala Gln Asn Glu Lys Ser Val Ala Asp Met
165 170 175
Ser Arg Ala Lys Gln Leu Lys Ser Leu Phe Arg Ile Ile Thr Pro Tyr
180 185 190
Phe Thr Met Leu Asp Ile Pro Cys Ile Ala Ile Asn His Thr Tyr Gln
195 200 205
Thr Gln Glu Met Tyr Ser Lys Thr Val Met Ser Gly Gly Thr Gly Ile
210 215 220
Met Tyr Ser Ala Asp Thr Val Ile Ile Leu Gly Lys Gln Gln Glu Lys
225 230 235 240
Asp Gly Lys Glu Ile Ile Gly Tyr His Phe Ile Met Asn Ile Glu Lys
245 250 255
Ser Arg Phe Val Lys Glu Lys Met Lys Val Pro Leu Thr Val Thr Tyr
260 265 270
Glu His Gly Ile Asp Gln Phe Ser Gly Leu Leu Asp Ile Ala Leu Gln
275 280 285
Thr Gly His Val Val Lys Pro Ser Asn Gly Trp Tyr Gln Arg Ala Phe
290 295 300
Ile Asp Glu Glu Thr Gly Glu Ile Glu Ile Glu Glu Lys Lys Tyr Arg
305 310 315 320
Ala Lys Glu Thr Gln Thr Leu Ser Phe Trp Lys Glu Ile Ile Asn Ser
325 330 335
Pro Thr Phe Lys Thr Gly Val Lys Arg Leu Tyr Cys Leu Gly Gln Leu
340 345 350
Asp Glu Ser Glu Leu Leu Asp Glu Val Asp Ser Leu Phe Asp
355 360 365
<210> 21
<211> 381
<212> PRT
<213> 肠杆菌噬菌体RB16
<400> 21
Met Ser Asn Lys Ala Leu Leu Lys Lys Leu Ile Lys Asn Ser Asn Ser
1 5 10 15
Gln Ser Ala Ser Ile Leu Ser Glu Ser Asp Val Phe Asn Asn Ile Thr
20 25 30
Lys Thr Arg Thr Arg Val Pro Ile Leu Asn Leu Val Leu Ser Gly Ala
35 40 45
Phe Asp Gly Gly Leu Thr Ser Gly Leu Thr Leu Ile Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Leu Gly Leu Val Ala Val Ala Ala Tyr Leu
65 70 75 80
Lys Ala Asn Glu Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Lys Gly
85 90 95
Val Thr Lys Ser Tyr Leu Lys Ser Met Gly Val Asp Pro Asp Arg Val
100 105 110
Val Tyr Thr Arg Ile Thr Thr Val Glu Gln Leu Arg Asn Asp Val Val
115 120 125
Ser Gln Leu Asp Ala Leu Glu Arg Gly Asp Lys Val Ile Ile Phe Val
130 135 140
Asp Ser Val Gly Asn Thr Ala Ser Lys Lys Glu Leu Lys Asp Ala Leu
145 150 155 160
Glu Asp Asn Asp Lys Gln Asp Met Thr Arg Ala Lys Ala Leu Lys Gly
165 170 175
Met Phe Arg Met Val Thr Pro Tyr Leu Ala Asp Ile Asp Ile Pro Met
180 185 190
Val Cys Ile Cys His Thr Tyr Asp Thr Gln Glu Met Tyr Ser Lys Lys
195 200 205
Val Ile Ser Gly Gly Thr Gly Leu Met Tyr Ser Ala Asp Thr Ala Ile
210 215 220
Ile Leu Gly Lys Gln Gln Val Lys Glu Gly Thr Glu Val Val Gly Tyr
225 230 235 240
Asp Phe Ile Met Asn Val Glu Lys Ser Arg Phe Val Lys Glu Lys Ser
245 250 255
Lys Phe Pro Leu His Val Thr Tyr Glu Gly Gly Ile Ser Met Phe Ser
260 265 270
Gly Leu Leu Asp Leu Ala Met Glu Met Asn Phe Val Gln Thr Pro Thr
275 280 285
Lys Gly Trp Arg Gly Arg Ala Phe Leu Asn Thr Glu Thr Gly Glu Leu
290 295 300
Glu Leu Glu Glu Lys Lys Trp Arg Glu Ala Glu Thr Asn Cys Ile Glu
305 310 315 320
Phe Trp Lys Pro Leu Phe Lys His Gln Pro Phe Ile Asp Ala Ile Gln
325 330 335
Asp Lys Tyr Arg Ile Pro Asp Lys Glu Ile Thr Asp Gly Ala Ala Leu
340 345 350
Glu Asp Leu Tyr Ser Asp Asp Val Val Glu Ser Asn Lys Val Asp Phe
355 360 365
Asp Asp Asp Ile Pro Asp Asp Val Asp Leu Met Glu Glu
370 375 380
<210> 22
<211> 391
<212> PRT
<213> 肠杆菌噬菌体T4
<400> 22
Met Ser Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser Lys Leu
1 5 10 15
Thr Ala Glu Leu Thr Ala Ser Lys Phe Phe Asn Glu Lys Asp Val Val
20 25 30
Arg Thr Lys Ile Pro Met Met Asn Ile Ala Leu Ser Gly Glu Ile Thr
35 40 45
Gly Gly Met Gln Ser Gly Leu Leu Ile Leu Ala Gly Pro Ser Lys Ser
50 55 60
Phe Lys Ser Asn Phe Gly Leu Thr Met Val Ser Ser Tyr Met Arg Gln
65 70 75 80
Tyr Pro Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Phe Gly Ile Thr
85 90 95
Pro Ala Tyr Leu Arg Ser Met Gly Val Asp Pro Glu Arg Val Ile His
100 105 110
Thr Pro Val Gln Ser Leu Glu Gln Leu Arg Ile Asp Met Val Asn Gln
115 120 125
Leu Asp Ala Ile Glu Arg Gly Glu Lys Val Val Val Phe Ile Asp Ser
130 135 140
Leu Gly Asn Leu Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu Asn Glu
145 150 155 160
Lys Val Val Ser Asp Met Thr Arg Ala Lys Thr Met Lys Ser Leu Phe
165 170 175
Arg Ile Val Thr Pro Tyr Phe Ser Thr Lys Asn Ile Pro Cys Ile Ala
180 185 190
Ile Asn His Thr Tyr Glu Thr Gln Glu Met Phe Ser Lys Thr Val Met
195 200 205
Gly Gly Gly Thr Gly Pro Met Tyr Ser Ala Asp Thr Val Phe Ile Ile
210 215 220
Gly Lys Arg Gln Ile Lys Asp Gly Ser Asp Leu Gln Gly Tyr Gln Phe
225 230 235 240
Val Leu Asn Val Glu Lys Ser Arg Thr Val Lys Glu Lys Ser Lys Phe
245 250 255
Lys Ile Asp Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser Gly Leu
260 265 270
Leu Asp Met Ala Leu Glu Leu Gly Phe Val Val Lys Pro Lys Asn Gly
275 280 285
Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met Ile Arg
290 295 300
Glu Glu Lys Ser Trp Arg Ala Lys Asp Thr Asn Cys Thr Thr Phe Trp
305 310 315 320
Gly Pro Leu Phe Lys His Gln Pro Phe Arg Asp Ala Ile Lys Arg Ala
325 330 335
Tyr Gln Leu Gly Ala Ile Asp Ser Asn Glu Ile Val Glu Ala Glu Val
340 345 350
Asp Glu Leu Ile Asn Ser Lys Val Glu Lys Phe Lys Ser Pro Glu Ser
355 360 365
Lys Ser Lys Ser Ala Ala Asp Leu Glu Thr Asp Leu Glu Gln Leu Ser
370 375 380
Asp Met Glu Glu Phe Asn Glu
385 390
<210> 23
<211> 393
<212> PRT
<213> 肠杆菌噬菌体T6
<400> 23
Met Ser Ile Ala Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser
1 5 10 15
Lys Met Thr Ala Glu Leu Thr Thr Ser Lys Phe Phe Asn Glu Lys Asp
20 25 30
Val Ile Arg Thr Lys Ile Pro Met Leu Asn Ile Ala Ile Ser Gly Ala
35 40 45
Ile Asp Gly Gly Met Gln Ser Gly Leu Thr Ile Phe Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Met Ser Leu Thr Met Val Ala Ala Tyr Leu
65 70 75 80
Asn Lys Tyr Pro Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Phe Gly
85 90 95
Ile Thr Pro Ala Tyr Leu Arg Ser Met Gly Val Asp Pro Glu Arg Val
100 105 110
Ile His Thr Pro Ile Gln Ser Val Glu Gln Leu Lys Ile Asp Met Val
115 120 125
Asn Gln Leu Glu Ala Ile Glu Arg Gly Glu Lys Val Ile Val Phe Ile
130 135 140
Asp Ser Ile Gly Asn Met Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu
145 150 155 160
Asn Glu Lys Ser Val Ala Asp Met Thr Arg Ala Lys Ser Leu Lys Ser
165 170 175
Leu Phe Arg Ile Val Thr Pro Tyr Phe Ser Ile Lys Asn Ile Pro Cys
180 185 190
Val Ala Val Asn His Thr Ile Glu Thr Ile Glu Met Phe Ser Lys Thr
195 200 205
Val Met Thr Gly Gly Thr Gly Val Met Tyr Ser Ala Asp Thr Val Phe
210 215 220
Ile Ile Gly Lys Arg Gln Ile Lys Asp Gly Ser Asp Leu Gln Gly Tyr
225 230 235 240
Gln Phe Val Leu Asn Val Glu Lys Ser Arg Thr Val Lys Glu Lys Ser
245 250 255
Lys Phe Lys Ile Asp Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser
260 265 270
Gly Leu Leu Asp Met Ala Leu Glu Leu Gly Phe Val Val Lys Pro Lys
275 280 285
Asn Gly Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met
290 295 300
Ile Arg Glu Glu Lys Ser Trp Arg Ala Lys Asp Thr Asn Cys Thr Thr
305 310 315 320
Phe Trp Gly Pro Leu Phe Lys His Gln Pro Phe Arg Asp Ala Ile Lys
325 330 335
Arg Ala Tyr Gln Leu Gly Ala Ile Asp Ser Asn Glu Ile Val Glu Ala
340 345 350
Glu Val Asp Glu Leu Ile Asn Ser Lys Val Glu Lys Phe Lys Ser Pro
355 360 365
Glu Ser Lys Ser Lys Ser Ala Ala Asp Leu Glu Thr Asp Leu Glu Gln
370 375 380
Leu Ser Asp Met Glu Glu Phe Asn Glu
385 390
<210> 24
<211> 387
<212> PRT
<213> 不动杆菌噬菌体133
<400> 24
Met Ser Ser Leu Lys Glu Arg Leu Ile Lys Ala Ser Thr Ser Lys Met
1 5 10 15
Thr Ala Glu Leu Thr Lys Ser Lys Phe Phe Asn Asp Lys Thr Val Val
20 25 30
Arg Thr Arg Ile Pro Met Leu Asn Ile Ala Ile Ser Gly Ala Leu Asn
35 40 45
Gly Gly Met Gln Ser Gly Leu Thr Ile Phe Ala Gly Pro Ser Lys His
50 55 60
Phe Lys Ser Asn Met Gly Leu Thr Met Val Ala Ala Tyr Met Lys Ala
65 70 75 80
Phe Pro Asp Ala Val Cys Met Phe Tyr Asp Ser Glu Phe Gly Ile Thr
85 90 95
Pro Ala Tyr Leu Lys Ala Met Gly Val Asp Pro Asp Arg Val Ile His
100 105 110
Thr Pro Val Gln Ser Val Glu Gln Leu Lys Ile Asp Met Thr Asn Gln
115 120 125
Leu Glu Glu Val Lys Arg Gly Glu Lys Val Ile Val Phe Ile Asp Ser
130 135 140
Ile Gly Asn Leu Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu Asn Glu
145 150 155 160
Lys Thr Thr Ala Asp Met Thr Arg Ala Lys Ala Leu Lys Ser Leu Phe
165 170 175
Arg Ile Val Thr Pro Tyr Phe Ser Ile Lys Asp Ile Pro Cys Val Ala
180 185 190
Val Asn His Thr Leu Gln Thr Leu Glu Met Phe Ser Lys Glu Val Met
195 200 205
Thr Gly Gly Thr Gly Val Met Tyr Ser Ala Asp Thr Val Phe Phe Ile
210 215 220
Gly Lys Arg Gln Val Lys Asp Gly Thr Glu Leu Ala Gly Tyr Glu Phe
225 230 235 240
Ile Leu Lys Ala Glu Lys Ser Arg Met Val Lys Glu Lys Ser Val Phe
245 250 255
Lys Ile Thr Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser Gly Leu
260 265 270
Leu Glu Met Ala Thr Asp Leu Gly Phe Val Val Lys Pro Lys Val Gly
275 280 285
Trp Tyr Lys Arg Ala Met Met Val Asp Gly Val Met Gln His Glu Glu
290 295 300
Lys Ser Trp Arg Ala Lys Asp Thr Asp Ser Ile Asp Phe Trp Gly Pro
305 310 315 320
Leu Phe Lys His Asp Glu Phe Arg Lys Ala Ile Glu Thr Arg Tyr Gln
325 330 335
Leu Gly Ser Ile Glu Ser Asp Ala Glu Val Asp Ala Glu Val Asp Ala
340 345 350
Leu Ile Gly Ser Lys Thr Thr Ala Lys Ile Ser Gly Val Asn Phe Gly
355 360 365
Pro Ala Glu Ser Ala Ala Asp Lys Glu Gln Gln Leu Glu Asp Phe Val
370 375 380
Asp Glu Asp
385
<210> 25
<211> 390
<212> PRT
<213> 肠杆菌噬菌体RB69
<400> 25
Met Ser Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser Lys Met
1 5 10 15
Thr Ala Asp Leu Thr Lys Ser Lys Leu Phe Asn Asn Arg Asp Glu Val
20 25 30
Pro Thr Arg Ile Pro Met Leu Asn Ile Ala Leu Gly Gly Ala Leu Asn
35 40 45
Ala Gly Leu Gln Ser Gly Leu Thr Ile Phe Ala Ala Pro Ser Lys His
50 55 60
Phe Lys Thr Leu Phe Gly Leu Thr Met Val Ala Ala Tyr Met Lys Lys
65 70 75 80
Tyr Lys Asp Ala Ile Cys Leu Phe Tyr Asp Ser Glu Phe Gly Ala Ser
85 90 95
Glu Ser Tyr Phe Arg Ser Met Gly Val Asp Leu Asp Arg Val Val His
100 105 110
Thr Pro Ile Gln Ser Val Glu Gln Leu Lys Val Asp Met Thr Asn Gln
115 120 125
Leu Asp Ala Ile Glu Arg Gly Asp Lys Val Ile Ile Phe Ile Asp Ser
130 135 140
Ile Gly Asn Thr Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu Asn Glu
145 150 155 160
Lys Val Val Gly Asp Met Ser Arg Ala Lys Ala Leu Lys Ser Leu Phe
165 170 175
Arg Ile Val Thr Pro Tyr Leu Thr Ile Lys Asp Ile Pro Cys Val Ala
180 185 190
Ile Asn His Thr Ala Met Glu Ile Gly Gly Leu Tyr Pro Lys Glu Ile
195 200 205
Met Gly Gly Gly Thr Gly Ile Leu Tyr Ser Ala Asn Thr Val Phe Phe
210 215 220
Ile Ser Lys Arg Gln Val Lys Glu Gly Thr Glu Leu Thr Gly Tyr Asp
225 230 235 240
Phe Thr Leu Lys Ala Glu Lys Ser Arg Thr Val Lys Glu Lys Ser Thr
245 250 255
Phe Lys Ile Thr Val Asn Phe Asp Gly Gly Ile Asp Pro Phe Ser Gly
260 265 270
Leu Leu Glu Met Ala Thr Glu Ile Gly Phe Val Val Lys Pro Lys Ala
275 280 285
Gly Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met Ile
290 295 300
Arg Glu Glu Lys Ser Trp Arg Ala Lys Ala Thr Asp Cys Val Glu Phe
305 310 315 320
Trp Gly Pro Leu Phe Lys His Lys Pro Phe Arg Asp Ala Ile Glu Thr
325 330 335
Lys Tyr Lys Leu Gly Ala Ile Ser Ser Ile Lys Glu Val Asp Asp Ala
340 345 350
Val Asn Asp Leu Ile Asn Cys Lys Ala Thr Thr Lys Val Pro Val Lys
355 360 365
Thr Ser Asp Ala Pro Ser Ala Ala Asp Ile Glu Asn Asp Leu Asp Glu
370 375 380
Met Glu Asp Phe Asp Glu
385 390
<210> 26
<211> 411
<212> PRT
<213> 气单胞菌噬菌体Aeh1
<400> 26
Met Ala Lys Gly Ile Lys Thr Ala Lys Thr Gly Asn Leu Gly Ser Leu
1 5 10 15
Met Ser Lys Leu Ala Gly Thr Ser Ser Asn Lys Met Ser Ser Val Leu
20 25 30
Ala Asp Ser Lys Phe Phe Asn Asp Lys Asp Cys Val Arg Thr Arg Val
35 40 45
Pro Leu Leu Asn Leu Ala Met Ser Gly Glu Leu Asp Gly Gly Leu Thr
50 55 60
Pro Gly Leu Thr Val Leu Ala Gly Pro Ser Lys His Phe Lys Ser Asn
65 70 75 80
Leu Ser Leu Val Phe Val Ala Ala Tyr Leu Arg Lys Tyr Pro Asp Ala
85 90 95
Val Cys Ile Phe Phe Asp Asn Glu Phe Gly Ser Thr Pro Gly Tyr Phe
100 105 110
Glu Ser Gln Gly Val Asp Ile Ser Arg Val Ile His Cys Pro Phe Lys
115 120 125
Asn Ile Glu Glu Leu Lys Phe Asp Ile Val Lys Lys Leu Glu Ala Ile
130 135 140
Glu Arg Gly Asp Arg Val Ile Val Phe Val Asp Ser Ile Gly Asn Ala
145 150 155 160
Ala Ser Lys Lys Glu Ile Asp Asp Ala Ile Asp Glu Lys Ser Val Ser
165 170 175
Asp Met Thr Arg Ala Lys Gln Ile Lys Ser Leu Thr Arg Met Met Thr
180 185 190
Pro Tyr Leu Thr Val Asn Asp Ile Pro Ala Ile Met Val Ala His Thr
195 200 205
Tyr Asp Thr Gln Glu Met Tyr Ser Lys Lys Val Val Ser Gly Gly Thr
210 215 220
Gly Ile Thr Tyr Ser Ser Asp Thr Val Ile Ile Ile Gly Arg Gln Gln
225 230 235 240
Glu Lys Asp Gly Lys Glu Leu Leu Gly Tyr Asn Phe Val Leu Asn Met
245 250 255
Glu Lys Ser Arg Phe Val Lys Glu Gln Ser Lys Leu Lys Leu Glu Val
260 265 270
Thr Phe Gln Gly Gly Ile Asn Thr Tyr Ser Gly Met Leu Asp Ile Ala
275 280 285
Leu Glu Val Gly Phe Val Val Lys Pro Ser Asn Gly Trp Phe Ser Arg
290 295 300
Ala Phe Leu Asp Glu Glu Thr Gly Glu Leu Val Glu Glu Asp Arg Lys
305 310 315 320
Trp Arg Arg Ala Asp Thr Asn Cys Leu Glu Phe Trp Lys Pro Met Phe
325 330 335
Ala His Gln Pro Phe Lys Thr Ala Cys Ser Asp Met Phe Lys Leu Lys
340 345 350
Ser Val Ala Val Lys Asp Glu Val Phe Asp Glu Val Asp Glu Leu Phe
355 360 365
Ser Gly Glu Ala Glu Met Pro Val Asn Met Gly Arg Lys Leu Asp Thr
370 375 380
Ala Asp Gln Glu Glu Ile Asp Gln Leu Glu Glu Val Asp Val Glu Gly
385 390 395 400
Ser Asp Ser Asp Glu Leu Phe Ala Asn Leu Asp
405 410
<210> 27
<211> 368
<212> PRT
<213> 气单胞菌噬菌体65
<400> 27
Met Ala Lys Lys Ala Lys Val Val Asn Ser Gly Asp Leu Leu Glu Arg
1 5 10 15
Leu Asn Gly Thr Ser Ser Asn Lys Met Ser Ala Met Leu Ala Glu Ser
20 25 30
Ile Phe Phe Asn Glu Lys Asp Thr Ile Arg Thr Arg Val Pro Ile Ile
35 40 45
Asn Leu Met Met Ser Gly Arg Leu Asp Gly Gly Ile Thr Pro Gly Leu
50 55 60
Thr Cys Ile Ala Gly Pro Ser Lys His Phe Lys Ser Asn Leu Ser Leu
65 70 75 80
Val Met Val Ser Ala Tyr Leu Arg Lys Tyr Pro Lys Ala Val Cys Leu
85 90 95
Phe Phe Asp Asn Glu Phe Gly Ser Thr Pro Asp Tyr Phe Thr Ser Gln
100 105 110
Gly Val Asp Ile Ser Arg Val Val His Cys Pro Phe Ile Asp Val Glu
115 120 125
Glu Leu Lys Phe Asp Ile Val Lys Lys Leu Glu Ser Ile Thr Arg Gly
130 135 140
Asp Lys Val Ile Ile Tyr Ile Asp Ser Ile Gly Asn Val Ala Ser Lys
145 150 155 160
Lys Glu Leu Gln Asp Ala Lys Asp Glu Lys Ser Ala Gln Asp Met Thr
165 170 175
Arg Ala Lys Gln Ile Lys Ser Leu Phe Arg Met Val Thr Pro Tyr Leu
180 185 190
Thr Val Leu Asp Ile Pro Cys Ile Ala Val Asn His Thr Tyr Glu Thr
195 200 205
Gln Glu Met Phe Ser Lys Thr Val Met Ser Gly Gly Thr Gly Pro Met
210 215 220
Tyr Ser Ala Asp Thr Val Ile Ile Leu Gly Lys Gln Gln Asp Lys Asp
225 230 235 240
Gly Lys Glu Leu Leu Gly Tyr Asn Phe Val Met Asn Ala Glu Lys Ser
245 250 255
Arg Ala Ile Lys Glu Lys Ser Lys Leu Lys Leu Met Val Ser Phe Glu
260 265 270
Gly Gly Ile Asn Thr Tyr Ser Gly Leu Leu Lys Ile Ala Gln Glu Leu
275 280 285
Gly Phe Val Thr Lys Pro Gln Asn Ala Arg Tyr Gln Arg Asn Phe Leu
290 295 300
Asp Leu Glu Pro Gly Glu Met Val Ile Pro Glu Asp Glu Lys Lys Trp
305 310 315 320
Thr Glu Glu Glu Ser Asp Ser Leu Glu Phe Trp Lys Pro Met Phe Ser
325 330 335
His Lys Pro Phe Met Asp Ala Val Ser Asn Ala Tyr Lys Leu Lys Ala
340 345 350
Val Glu Val Ser Gln Glu Val Phe Asp Glu Val Asp Gln Leu Phe Gly
355 360 365
<210> 28
<211> 366
<212> PRT
<213> 弧菌噬菌体KVP40
<400> 28
Met Ser Asp Leu Met Lys Ser Leu Lys Lys Ser Ser Thr Ser Gly Tyr
1 5 10 15
Ala Gln Val Leu Ser Glu Ser Gln Phe Met Phe Asp Lys Asp His Thr
20 25 30
Arg Thr Tyr Val Pro Ala Ile Asn Ile Ala Phe Ser Gly Glu Val Asp
35 40 45
Gly Gly Leu Thr Ser Gly Leu Thr Val Leu Ala Gly Pro Ser Lys His
50 55 60
Phe Lys Ser Asn Leu Gly Leu Val Gly Val Ala Ala Tyr Leu Lys Lys
65 70 75 80
Tyr Pro Asp Ala Val Cys Val Phe Ile Asp Thr Glu Phe Gly Ile Thr
85 90 95
Pro Ser Tyr Leu Arg Ser Gln Gly Val Asp Pro Asp Arg Val Leu His
100 105 110
Ile Gln Cys Glu Ser Val Glu Arg Met Lys Phe Glu Met Ala Asn Gln
115 120 125
Leu Lys Asp Leu Ala Glu Arg Lys Arg Ala Lys Lys Ala Gly Glu Glu
130 135 140
Pro Asp Arg Val Ile Phe Phe Ile Asp Ser Val Gly Asn Val Ala Ser
145 150 155 160
Ala Lys Glu Ile Asp Asp Ala Gln Asn Glu Lys Ser Val Ala Asp Met
165 170 175
Ser Arg Ala Lys Gln Leu Lys Ser Leu Phe Arg Ile Ile Thr Pro Tyr
180 185 190
Phe Thr Met Leu Asp Ile Pro Cys Ile Ala Ile Asn His Thr Tyr Gln
195 200 205
Thr Gln Glu Ile Tyr Ser Lys Thr Val Met Ser Gly Gly Thr Gly Ile
210 215 220
Met Tyr Ser Ala Asp Thr Val Ile Ile Leu Gly Lys Gln Gln Glu Lys
225 230 235 240
Asp Gly Lys Asp Ile Ile Gly Tyr His Phe Ile Met Asn Ile Glu Lys
245 250 255
Ser Arg Phe Val Lys Glu Lys Met Lys Val Lys Leu Thr Val Thr Tyr
260 265 270
Glu Asn Gly Ile Asp Pro Phe Ser Gly Leu Leu Asp Ile Ala Leu Gln
275 280 285
Thr Gly His Val Val Lys Pro Ser Asn Gly Trp Tyr Gln Arg Ala Thr
290 295 300
Val Asp Glu Glu Thr Gly Glu Met Ile Val Glu Glu Lys Lys Tyr Arg
305 310 315 320
Ala Lys Glu Thr Gln Thr Ile Ser Phe Trp Lys Asp Ile Ile Asn Ser
325 330 335
Pro Thr Phe Lys Glu Gly Val Lys Arg Ile Tyr Cys Leu Gly Gln Leu
340 345 350
Asp Glu Ser Glu Leu Phe Gly Glu Val Asp Ser Leu Phe Asp
355 360 365
<210> 29
<211> 386
<212> PRT
<213> 肠杆菌噬菌体RB43
<400> 29
Met Ser Asn Lys Ala Leu Leu Lys Lys Leu Ile Lys Asn Ser Asn Ser
1 5 10 15
Gln Ser Ala Ala Ile Leu Ser Glu Ser Asp Val Phe Asn Asn Ile Thr
20 25 30
Lys Thr Arg Thr Arg Val Pro Ile Leu Asn Leu Ala Leu Ser Gly Ala
35 40 45
Phe Asp Gly Gly Leu Thr Ser Gly Leu Thr Leu Phe Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Leu Gly Leu Val Thr Val Ser Ala Tyr Leu
65 70 75 80
Lys Ala Asn Glu Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Lys Gly
85 90 95
Val Thr Lys Ser Tyr Leu Lys Ser Met Gly Val Asp Pro Asp Arg Val
100 105 110
Val Tyr Thr Arg Ile Thr Thr Val Glu Gln Leu Arg Asn Asp Val Val
115 120 125
Ser Gln Leu Asp Ala Leu Glu Arg Gly Asp Lys Val Ile Ile Phe Val
130 135 140
Asp Ser Val Gly Asn Thr Ala Ser Lys Lys Glu Leu Ala Asp Ala Leu
145 150 155 160
Ser Asp Asn Asp Lys Gln Asp Met Thr Arg Ala Lys Ala Leu Lys Gly
165 170 175
Met Phe Arg Met Val Thr Pro Tyr Leu Ala Asp Leu Asp Ile Pro Met
180 185 190
Val Cys Ile Cys His Thr Tyr Asp Thr Gln Glu Met Tyr Ser Lys Lys
195 200 205
Val Ile Ser Gly Gly Thr Gly Leu Met Tyr Ser Ala Asp Thr Ala Ile
210 215 220
Ile Leu Gly Lys Gln Gln Val Lys Glu Gly Thr Glu Val Val Gly Tyr
225 230 235 240
Asp Phe Ile Met Asn Ile Glu Lys Ser Arg Phe Val Lys Glu Lys Ser
245 250 255
Lys Phe Lys Leu His Val Thr Tyr Glu Gly Gly Ile Ser Met Tyr Ser
260 265 270
Gly Leu Leu Asp Leu Ala Met Glu Met Asn Phe Val Gln Thr Pro Thr
275 280 285
Lys Gly Trp Arg Gly Arg Ala Phe Leu Asn Thr Glu Thr Gly Glu Leu
290 295 300
Glu Leu Glu Glu Lys Lys Trp Arg Glu Ser Glu Thr Asn Ser Ile Glu
305 310 315 320
Phe Trp Arg Pro Leu Phe Thr His Gln Pro Phe Leu Asp Ala Ile Gln
325 330 335
Asp Lys Tyr Arg Ile Pro Asp Lys Glu Ile Thr Asp Gly Ala Ala Leu
340 345 350
Glu Asp Leu Tyr Ser Thr Asp Glu Pro Glu Ser Asn Lys Ile Asp Leu
355 360 365
Asp Asp Asp Ile Pro Asp Asp Ile Gly Ile Asp Gln Asp Glu Glu Pro
370 375 380
Ile Met
385
<210> 30
<211> 335
<212> PRT
<213> 原绿球藻噬菌体P-SSM2
<400> 30
Met Asp Phe Leu Lys Glu Ile Val Lys Glu Ile Gly Asp Glu Tyr Thr
1 5 10 15
Gln Val Ala Ala Asp Ile Gln Glu Asn Glu Arg Phe Ile Asp Thr Gly
20 25 30
Ser Tyr Ile Phe Asn Gly Leu Val Ser Gly Ser Ile Phe Gly Gly Val
35 40 45
Ser Ser Ser Arg Ile Thr Ala Ile Ala Gly Glu Ser Ser Thr Gly Lys
50 55 60
Thr Tyr Phe Ser Leu Ala Val Val Lys Asn Phe Leu Asp Asn Asn Pro
65 70 75 80
Asp Gly Tyr Cys Leu Tyr Phe Asp Thr Glu Ala Ala Val Asn Lys Gly
85 90 95
Leu Leu Glu Ser Arg Gly Ile Asp Met Asn Arg Leu Val Val Val Asn
100 105 110
Val Val Thr Ile Glu Glu Phe Arg Ser Lys Ala Leu Arg Ala Val Asp
115 120 125
Ile Tyr Leu Lys Thr Ser Glu Glu Glu Arg Lys Pro Cys Met Phe Val
130 135 140
Leu Asp Ser Leu Gly Met Leu Ser Thr Glu Lys Glu Ile Arg Asp Ala
145 150 155 160
Leu Asp Asp Lys Gln Val Arg Asp Met Thr Lys Ser Gln Leu Val Lys
165 170 175
Gly Ala Phe Arg Met Leu Thr Leu Lys Leu Gly Gln Ala Asn Ile Pro
180 185 190
Leu Ile Val Thr Asn His Thr Tyr Asp Val Ile Gly Ser Tyr Val Pro
195 200 205
Thr Lys Glu Met Gly Gly Gly Ser Gly Leu Lys Tyr Ala Ala Ser Thr
210 215 220
Ile Ile Tyr Leu Ser Lys Lys Lys Glu Lys Asp Gln Lys Glu Val Ile
225 230 235 240
Gly Asn Leu Ile Lys Ala Lys Thr His Lys Ser Arg Leu Ser Lys Glu
245 250 255
Asn Lys Glu Val Lys Ile Arg Leu Tyr Tyr Asp Glu Arg Gly Leu Asp
260 265 270
Arg Tyr Tyr Gly Leu Leu Glu Leu Gly Glu Ile Gly Gly Met Trp Lys
275 280 285
Asn Val Ala Gly Arg Tyr Glu Met Asn Gly Lys Lys Ile Tyr Ala Lys
290 295 300
Glu Ile Leu Lys Asn Pro Thr Glu Tyr Phe Thr Asp Asp Ile Met Glu
305 310 315 320
Gln Leu Asp Asn Ile Ala Lys Glu His Phe Ser Tyr Gly Thr Asn
325 330 335
<210> 31
<211> 336
<212> PRT
<213> 原绿球藻噬菌体P-SSM4
<400> 31
Met Asn Phe Leu Lys Asp Ile Ala Lys Glu Ile Gly Asn Asp Tyr Ala
1 5 10 15
Ser Leu Val Ser Glu Gly Val Ser Ala Gly Asp Thr Ala Gly Phe Ile
20 25 30
Asp Thr Gly Ser Tyr Ile Phe Asn Ala Leu Leu Ser Gly Ser Ile Tyr
35 40 45
Gly Gly Ile Pro Asn Asn Lys Ile Thr Ala Ile Ala Gly Glu Thr Ser
50 55 60
Thr Gly Lys Thr Phe Phe Cys Leu Gly Met Val Gln His Phe Leu Glu
65 70 75 80
Ser Asn Pro Asp Ala Gly Val Ile Tyr Phe Glu Ser Glu Ser Ala Ile
85 90 95
Ser Lys Gln Met Ile Glu Asp Arg Gly Ile Asp Ser Asn Arg Met Leu
100 105 110
Leu Val Pro Val Thr Thr Val Gln Glu Phe Arg Leu Gln Ala Ile Lys
115 120 125
Ile Leu Asp Lys Tyr Asn Glu Gln Thr Ala Glu Glu Arg Lys Pro Leu
130 135 140
Met Phe Val Leu Asp Ser Leu Gly Met Leu Ser Thr Ser Lys Glu Val
145 150 155 160
Glu Asp Ser Glu Ala Gly Lys Glu Thr Arg Asp Met Thr Arg Ala Gln
165 170 175
Val Val Lys Ser Ile Phe Arg Val Leu Thr Leu Lys Leu Gly Lys Ala
180 185 190
Asn Val Pro Leu Ile Val Thr Asn His Thr Tyr Asp Val Val Gly Ala
195 200 205
Tyr Ile Pro Thr Lys Glu Met Gly Gly Gly Ser Gly Leu Lys Tyr Ala
210 215 220
Ala Ser Thr Ile Val Tyr Leu Ser Lys Lys Lys Glu Lys Asn Gly Lys
225 230 235 240
Glu Val Val Gly Asn Ile Ile Lys Cys Lys Thr Ala Lys Ser Arg Leu
245 250 255
Thr Lys Glu Asn Ser Asp Val Lys Thr Arg Leu Tyr Tyr Asp Arg Gly
260 265 270
Leu Asp Arg Tyr Tyr Gly Leu Leu Glu Leu Gly Glu Lys His Gly Val
275 280 285
Phe Ser Arg Lys Gly Asn Arg Val Val Val Gly Asp Ser Ser Val Tyr
290 295 300
Pro Ser Ala Ile Leu Ala Asp Pro Asp Lys Tyr Phe Thr Glu Glu Leu
305 310 315 320
Met Glu Lys Leu Asp Glu Ala Ala Ala Lys Glu Phe Arg Tyr Gly Asn
325 330 335
<210> 32
<211> 343
<212> PRT
<213> 聚球藻噬菌体S-PM2
<400> 32
Met Ser Phe Leu Asp Ser Val Ile Lys Asp Ser Lys Asn Glu Tyr Ala
1 5 10 15
Ala Phe Ala Ser Glu Gly Val Ala Ala Gly Asp Val Glu Ser Phe Val
20 25 30
Asp Thr Gly Ser Tyr Ile Phe Asn Ala Leu Val Ser Gly Ser Ile Phe
35 40 45
Gly Gly Ile Pro Ser Asn Lys Ile Thr Ala Leu Ala Gly Glu Ser Gly
50 55 60
Thr Gly Lys Thr Phe Phe Cys Leu Ser Val Val Arg Asn Phe Leu Asn
65 70 75 80
Thr Asp Pro Asp Ala Gly Val Ile Tyr Phe Glu Thr Glu Ser Ala Ile
85 90 95
Ser Lys Gln Met Ile Glu Ser Arg Gly Ile Asp Ser Thr Arg Met Ile
100 105 110
Ile Phe Pro Val Asp Thr Ile Glu Asp Phe Arg Thr Gln Ala Val Arg
115 120 125
Ile Ile Asp Lys Tyr Met Glu Gln Asn Lys Ser Glu Arg Lys Pro Leu
130 135 140
Met Phe Val Leu Asp Ser Leu Gly Met Leu Ala Thr Lys Lys Glu Val
145 150 155 160
Glu Asp Ala Ser Asn Asp Lys Gln Val Arg Asp Met Thr Lys Ala Gln
165 170 175
Ile Val Lys Ser Ala Phe Arg Ile Leu Thr Leu Lys Met Gly Lys Ala
180 185 190
Asn Ile Pro Met Leu Val Thr Asn His Thr Tyr Asp Val Val Gly Ser
195 200 205
Tyr Val Pro Thr Lys Glu Met Gly Gly Gly Ser Gly Leu Lys Tyr Ser
210 215 220
Ala Ser Thr Ile Val Tyr Leu Gly Lys Lys Lys Glu Lys Asp Gly Thr
225 230 235 240
Asp Leu Val Gly Asn Ile Ile Lys Cys Glu Ala Lys Lys Ser Arg Leu
245 250 255
Thr Arg Glu Gly Ser Lys Val Lys Thr Arg Leu Phe Phe Asp Gln Arg
260 265 270
Gly Leu Glu Arg Tyr Tyr Gly Met Leu Glu Leu Gly Glu Arg Ala Gly
275 280 285
Leu Trp Lys Asn Thr Ala Gly Arg Tyr Glu Ile Asn Gly Lys Lys Val
290 295 300
Tyr Gly Lys Gln Ile Leu Ala Asn Pro Asp Glu Phe Phe Thr Glu Glu
305 310 315 320
Ile Leu Gln Glu Leu Asp Lys Gln Ala Gln Arg Glu Phe Leu Tyr Gly
325 330 335
Ala Ser Asp Asp Gly Glu Asp
340
<210> 33
<211> 393
<212> PRT
<213> 肠杆菌噬菌体RB32
<400> 33
Met Ser Ile Ala Asp Leu Lys Ser Arg Leu Ile Lys Ala Ser Thr Ser
1 5 10 15
Lys Met Thr Ala Glu Leu Thr Thr Ser Lys Phe Phe Asn Glu Lys Asp
20 25 30
Val Ile Arg Thr Lys Ile Pro Met Leu Asn Ile Ala Ile Ser Gly Ala
35 40 45
Ile Asp Gly Gly Met Gln Ser Gly Leu Thr Ile Phe Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Met Ser Leu Thr Met Val Ala Ala Tyr Leu
65 70 75 80
Asn Lys Tyr Pro Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Phe Gly
85 90 95
Ile Thr Pro Ala Tyr Leu Arg Ser Met Gly Val Asp Pro Glu Arg Val
100 105 110
Ile His Thr Pro Ile Gln Ser Val Glu Gln Leu Lys Ile Asp Met Val
115 120 125
Asn Gln Leu Glu Ala Ile Glu Arg Gly Glu Lys Val Ile Val Phe Ile
130 135 140
Asp Ser Ile Gly Asn Met Ala Ser Lys Lys Glu Thr Glu Asp Ala Leu
145 150 155 160
Asn Glu Lys Ser Val Ala Asp Met Thr Arg Ala Lys Ser Leu Lys Ser
165 170 175
Leu Phe Arg Ile Val Thr Pro Tyr Phe Ser Ile Lys Asn Ile Pro Cys
180 185 190
Val Ala Val Asn His Thr Ile Glu Thr Ile Glu Met Phe Ser Lys Thr
195 200 205
Val Met Thr Gly Gly Thr Gly Val Met Tyr Ser Ala Asp Thr Val Phe
210 215 220
Ile Ile Gly Lys Arg Gln Ile Lys Asp Gly Ser Asp Leu Gln Gly Tyr
225 230 235 240
Gln Phe Val Leu Asn Val Glu Lys Ser Arg Thr Val Lys Glu Lys Ser
245 250 255
Lys Phe Lys Ile Asp Val Lys Phe Asp Gly Gly Ile Asp Pro Tyr Ser
260 265 270
Gly Leu Leu Asp Met Ala Leu Glu Leu Gly Phe Val Val Lys Pro Lys
275 280 285
Asn Gly Trp Tyr Ala Arg Glu Phe Leu Asp Glu Glu Thr Gly Glu Met
290 295 300
Ile Arg Glu Glu Lys Ser Trp Arg Ala Lys Asp Thr Asn Cys Thr Thr
305 310 315 320
Phe Trp Gly Pro Leu Phe Lys His Gln Pro Phe Arg Asp Ala Ile Lys
325 330 335
Arg Ala Tyr Gln Leu Gly Ala Ile Asp Ser Asn Glu Ile Val Glu Ala
340 345 350
Glu Val Asp Glu Leu Ile Asn Ser Lys Val Glu Lys Phe Lys Ser Pro
355 360 365
Glu Ser Lys Ser Lys Ser Ala Ala Asp Leu Glu Thr Asp Leu Glu Gln
370 375 380
Leu Ser Asp Met Glu Glu Phe Asn Glu
385 390
<210> 34
<211> 366
<212> PRT
<213> 弧菌噬菌体nt-1
<400> 34
Met Ser Asp Leu Leu Lys Ser Leu Lys Lys Ser Ser Thr Ser Gly Tyr
1 5 10 15
Ala His Val Leu Ser Glu Ser Gln Phe Met Phe Glu Lys Asp His Thr
20 25 30
Arg Thr Tyr Val Pro Ala Ile Asn Ile Ala Phe Ser Gly Glu Val Asp
35 40 45
Gly Gly Leu Thr Ser Gly Leu Thr Val Leu Ala Gly Pro Ser Lys His
50 55 60
Phe Lys Ser Asn Leu Gly Leu Val Gly Val Ala Ala Tyr Leu Lys Lys
65 70 75 80
Tyr Pro Glu Ala Ile Cys Val Phe Ile Asp Thr Glu Phe Gly Ile Thr
85 90 95
Pro Ser Tyr Leu Lys Ser Gln Gly Val Asp Pro Glu Arg Val Leu His
100 105 110
Ile Gln Cys Glu Ser Val Glu Arg Met Lys Phe Glu Met Ala Asn Gln
115 120 125
Leu Lys Asp Leu Ala Glu Arg Lys Arg Ala Lys Lys Ala Gly Glu Glu
130 135 140
Pro Asp Arg Val Val Phe Phe Ile Asp Ser Val Gly Asn Val Ala Ser
145 150 155 160
Ala Lys Glu Ile Asp Asp Ala Gln Asn Glu Lys Ser Val Ala Asp Met
165 170 175
Ser Arg Ala Lys Gln Leu Lys Ser Leu Phe Arg Ile Ile Thr Pro Tyr
180 185 190
Phe Thr Met Leu Asp Ile Pro Cys Ile Ala Ile Asn His Thr Tyr Gln
195 200 205
Thr Gln Glu Met Tyr Ser Lys Thr Val Met Ser Gly Gly Thr Gly Ile
210 215 220
Met Tyr Ser Ala Asp Thr Val Ile Ile Leu Gly Lys Gln Gln Glu Lys
225 230 235 240
Asp Gly Lys Glu Ile Ile Gly Tyr His Phe Ile Met Asn Ile Glu Lys
245 250 255
Ser Arg Phe Val Lys Glu Lys Met Lys Val Lys Leu Thr Val Thr Tyr
260 265 270
Glu His Gly Ile Asp Gln Phe Ser Gly Leu Leu Asp Ile Ala Leu Gln
275 280 285
Thr Gly His Val Val Lys Pro Ser Asn Gly Trp Tyr Gln Arg Ala Phe
290 295 300
Ile Asp Glu Glu Thr Gly Glu Ile Glu Ile Glu Glu Lys Lys Tyr Arg
305 310 315 320
Ala Lys Glu Thr Gln Thr Leu Ser Phe Trp Lys Glu Ile Ile Asn Ser
325 330 335
Pro Thr Phe Lys Thr Gly Val Lys Arg Leu Tyr Cys Leu Gly Gln Leu
340 345 350
Asp Glu Ser Glu Leu Leu Asp Glu Val Asp Ser Leu Phe Asp
355 360 365
<210> 35
<211> 381
<212> PRT
<213> 肠杆菌噬菌体RB16
<400> 35
Met Ser Asn Lys Ala Leu Leu Lys Lys Leu Ile Lys Asn Ser Asn Ser
1 5 10 15
Gln Ser Ala Ser Ile Leu Ser Glu Ser Asp Val Phe Asn Asn Ile Thr
20 25 30
Lys Thr Arg Thr Arg Val Pro Ile Leu Asn Leu Val Leu Ser Gly Ala
35 40 45
Phe Asp Gly Gly Leu Thr Ser Gly Leu Thr Leu Ile Ala Gly Pro Ser
50 55 60
Lys His Phe Lys Ser Asn Leu Gly Leu Val Ala Val Ala Ala Tyr Leu
65 70 75 80
Lys Ala Asn Glu Asp Ala Val Cys Leu Phe Tyr Asp Ser Glu Lys Gly
85 90 95
Val Thr Lys Ser Tyr Leu Lys Ser Met Gly Val Asp Pro Asp Arg Val
100 105 110
Val Tyr Thr Arg Ile Thr Thr Val Glu Gln Leu Arg Asn Asp Val Val
115 120 125
Ser Gln Leu Asp Ala Leu Glu Arg Gly Asp Lys Val Ile Ile Phe Val
130 135 140
Asp Ser Val Gly Asn Thr Ala Ser Lys Lys Glu Leu Lys Asp Ala Leu
145 150 155 160
Glu Asp Asn Asp Lys Gln Asp Met Thr Arg Ala Lys Ala Leu Lys Gly
165 170 175
Met Phe Arg Met Val Thr Pro Tyr Leu Ala Asp Ile Asp Ile Pro Met
180 185 190
Val Cys Ile Cys His Thr Tyr Asp Thr Gln Glu Met Tyr Ser Lys Lys
195 200 205
Val Ile Ser Gly Gly Thr Gly Leu Met Tyr Ser Ala Asp Thr Ala Ile
210 215 220
Ile Leu Gly Lys Gln Gln Val Lys Glu Gly Thr Glu Val Val Gly Tyr
225 230 235 240
Asp Phe Ile Met Asn Val Glu Lys Ser Arg Phe Val Lys Glu Lys Ser
245 250 255
Lys Phe Lys Leu His Val Thr Tyr Glu Gly Gly Ile Ser Met Phe Ser
260 265 270
Gly Leu Leu Asp Leu Ala Met Glu Met Asn Phe Val Gln Thr Pro Thr
275 280 285
Lys Gly Trp Arg Gly Arg Ala Phe Leu Asn Thr Glu Thr Gly Glu Leu
290 295 300
Glu Leu Glu Glu Lys Lys Trp Arg Glu Ala Glu Thr Asn Cys Ile Glu
305 310 315 320
Phe Trp Lys Pro Leu Phe Lys His Gln Pro Phe Ile Asp Ala Ile Gln
325 330 335
Asp Lys Tyr Arg Ile Pro Asp Lys Glu Ile Thr Asp Gly Ala Ala Leu
340 345 350
Glu Asp Leu Tyr Ser Asp Asp Val Val Glu Ser Asn Lys Val Asp Phe
355 360 365
Asp Asp Asp Ile Pro Asp Asp Val Asp Leu Met Glu Glu
370 375 380

Claims (39)

1.重组UvsX,所述重组UvsX包含与SEQ ID NO:1至少60%、70%、80%、90%、95%、99%相同的氨基酸序列,所述重组UvsX包含在功能上等同于RB49 UvsX氨基酸序列中Pro256的位置处的氨基酸取代突变。
2.权利要求1的重组UvsX,其中所述取代突变包含突变为带电荷的残基。
3.权利要求1的重组UvsX,其中所述取代突变包含突变为碱性残基。
4.权利要求1的重组UvsX,其中所述取代突变包含与所述RB49 UvsX氨基酸序列中Pro256Lys同源的突变。
5.权利要求1-4中任一项的重组UvsX,其中所述重组UvsX还包含在功能上等同于RB49UvsX氨基酸序列中His63的位置处的取代突变。
6.权利要求5的重组UvsX,其中所述重组UvsX包含与RB49 UvsX氨基酸序列中His63Ser同源的取代突变。
7.权利要求1-6中任一项的重组UvsX,其中所述重组UvsX还包含选自下组的突变:在C末端添加一个或多个谷氨酸残基;在C末端添加一个或多个天冬氨酸残基;及其组合。
8.权利要求1-7中任一项的重组UvsX,其中所述重组UvsX衍生自选自下组的肌病毒科(myoviridae)噬菌体:T4、T6、Rb69、Aeh1、KVP40、不动杆菌噬菌体(Acinetobacter phage)133、气单胞菌噬菌体(Aeromonas phage)65、噬蓝藻体P-SSM2、噬蓝藻体PSSM4、噬蓝藻体S-PM2、Rb32、弧菌噬菌体nt-1、Rb16、Rb43,和Rb49。
9.权利要求1-7中任一项的重组UvsX,其中所述重组UvsX衍生自选自下组的肌病毒科噬菌体:T2、Rb14、气单胞菌噬菌体25、phi-1、噬菌体31、噬菌体44RR2.8t、噬菌体Rb3、和噬菌体LZ2。
10.重组UvsX,其包含SEQ ID NO:2和22-35中任一个的氨基酸序列。
11.重组UvsX,其包含对半保守域的取代突变,所述半保守域包含SEQ ID NO:3-5中任一项的氨基酸序列,其中所述取代突变包含选自下组的突变:在位置7处取代为除Phe、Pro、Asp、Glu或Asn以外的任何残基。
12.权利要求11的重组UvsX,其中所述突变包含突变为带电荷的残基。
13.权利要求11的重组UvsX,其中所述突变包含在位置7处取代为Lys。
14.重组UvsX,其包含对半保守域的取代突变,所述半保守域包含SEQ ID NO:6-7中任一项的氨基酸序列,其中所述取代突变包含选自下组的突变:在位置12处突变为除Phe、Pro、Asp、Glu或Asn以外的任何残基。
15.权利要求14的重组UvsX,其中所述突变包含突变为带电荷的残基。
16.权利要求14的重组UvsX,其中所述突变包含在位置12处取代为Lys。
17.权利要求10-15中任一项的重组UvsX,其中所述重组UvsX还包含功能上等同于RB49UvsX氨基酸序列中His63的位置处的取代突变。
18.权利要求17的重组UvsX,其中所述重组UvsX包含与RB49 UvsX氨基酸序列中His63Ser同源的取代突变。
19.权利要求10-18中任一项的重组UvsX,其中所述重组UvsX还包含选自下组的突变:在C末端添加一个或多个谷氨酸残基;在C末端添加一个或多个天冬氨酸残基;及其组合。
20.权利要求10-19中任一项的重组UvsX,其中所述重组UvsX衍生自选自下组的肌病毒科噬菌体:T4、T6、Rb69、Aeh1、KVP40、不动杆菌噬菌体133、气单胞菌噬菌体65、噬蓝藻体P-SSM2、噬蓝藻体PSSM4、噬蓝藻体S-PM2、Rb32、弧菌噬菌体nt-1、Rb16、Rb43,和Rb49。
21.权利要求10-19中任一项的重组UvsX,其中所述重组UvsX衍生自选自下组的肌病毒科噬菌体:T2、Rb14、气单胞菌噬菌体25、phi-1、噬菌体31、噬菌体44RR2.8t、噬菌体Rb3,和噬菌体LZ2。
22.编码如权利要求1-21中任一项所定义的重组UvsX的核酸分子。
23.表达载体,其包含权利要求22的核酸分子。
24.宿主细胞,其包含权利要求23的载体。
25.扩增靶核酸分子的重组酶聚合酶扩增方法,其包含以下步骤:(a)将权利要求1-21中任一项的重组UvsX与第一和第二核酸引物接触以形成第一和第二核蛋白引物,其中所述核酸引物包含在其3’端的单链区;(b)将所述第一和第二核蛋白引物与所述靶核酸分子接触,从而在所述第一链的第一部分处形成第一双链结构并且在所述第二链的第二部分处形成第二双链结构,从而所述第一核酸引物和所述第二核酸引物的3’端在相同的双链模板核酸分子上彼此相对取向;(c)用一种或多种聚合酶和dNTP延伸所述第一和第二核酸引物的3’端以产生第一和第二双链核酸和核酸的第一和第二置换链;并且(d)通过重复(b)和(c)继续反应,直到达到期望的扩增程度。
26.权利要求25的方法,其中所述靶核酸分子包含双链核酸。
27.权利要求25的方法,其中所述靶核酸分子包含单链衔接头区。
28.权利要求25的方法,其中在重组酶加载蛋白(loading protein)存在下进行所述方法。
29.权利要求28的方法,其中所述重组酶加载蛋白选自下组:T4UvsY、大肠杆菌recO、大肠杆菌recR,及其组合。
30.权利要求25的方法,其中在选自下组的单链稳定剂的存在下进行所述方法:gp32、大肠杆菌SSB蛋白、T4gp32蛋白,及其衍生物。
31.权利要求25的方法,其中在选自下组的拥挤剂(crowding agent)的存在下进行所述方法:聚乙二醇,聚环氧乙烷(polyethylene oxide),聚苯乙烯,Ficoll,葡聚糖,PVP,和白蛋白,使得所述拥挤剂刺激扩增。
32.权利要求25的方法,其中在扩增位点的阵列上进行所述方法。
33.权利要求32的方法,其中每个扩增位点包含多个用于扩增所述靶核酸的扩增引物。
34.权利要求32的方法,其中所述扩增位点的阵列包含表面上的特征阵列。
35.权利要求34的方法,其中所述特征是不连续的,并且由缺少所述扩增引物的表面的间隙区域分开。
36.权利要求32的方法,其中所述扩增位点的阵列包含溶液中的珠粒或表面上的珠粒。
37.权利要求32的方法,其中所述扩增位点的阵列包含乳液。
38.权利要求25的方法,其中等温发生所述方法。
39.用于进行重组酶聚合酶反应的试剂盒,其包含:如权利要求1-21中任一项定义的重组UvsX以及如下的一项或多项:
单链DNA结合蛋白;
DNA聚合酶;
dNTP或dNTP和ddNTP的混合物;
拥挤剂;
缓冲液;
还原剂;
ATP或ATP类似物;
重组酶加载蛋白;
第一引物和任选地第二引物。
CN201580059870.9A 2014-09-29 2015-09-29 重组酶突变体 Active CN107208075B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462057056P 2014-09-29 2014-09-29
US62/057,056 2014-09-29
PCT/US2015/053012 WO2016054088A1 (en) 2014-09-29 2015-09-29 Recombinase mutants

Publications (2)

Publication Number Publication Date
CN107208075A true CN107208075A (zh) 2017-09-26
CN107208075B CN107208075B (zh) 2021-08-24

Family

ID=54293382

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580059870.9A Active CN107208075B (zh) 2014-09-29 2015-09-29 重组酶突变体

Country Status (18)

Country Link
US (2) US9982244B2 (zh)
EP (1) EP3201222B1 (zh)
JP (2) JP2017529093A (zh)
KR (3) KR20200026320A (zh)
CN (1) CN107208075B (zh)
AU (1) AU2015323936B2 (zh)
BR (1) BR112017006542B1 (zh)
CA (1) CA2962941C (zh)
DK (1) DK3201222T3 (zh)
ES (1) ES2729302T3 (zh)
IL (1) IL251422B (zh)
MX (1) MX2017004034A (zh)
MY (1) MY182395A (zh)
NZ (1) NZ730593A (zh)
RU (1) RU2721920C2 (zh)
SG (1) SG11201702493WA (zh)
WO (1) WO2016054088A1 (zh)
ZA (1) ZA201702248B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108913700A (zh) * 2018-08-16 2018-11-30 深圳市艾伟迪生物科技有限公司 gp32单链结合蛋白的制备方法、表达基因、重组表达载体及应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054088A1 (en) * 2014-09-29 2016-04-07 Illumina Cambridge Limited Recombinase mutants
EP3436471B1 (en) * 2016-03-28 2021-11-03 Illumina, Inc. Recombinase mutants
US11268137B2 (en) * 2016-12-09 2022-03-08 Boreal Genomics, Inc. Linked ligation
GB201704754D0 (en) 2017-01-05 2017-05-10 Illumina Inc Kinetic exclusion amplification of nucleic acid libraries

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035205A2 (en) * 2006-05-04 2008-03-27 Asm Scientific, Inc. Recombinase polymerase amplification
WO2010141940A1 (en) * 2009-06-05 2010-12-09 Alere San Diego, Inc. Recombinase polymerase amplification reagents and kits
WO2013188582A1 (en) * 2012-06-15 2013-12-19 Illumina, Inc. Kinetic exclusion amplification of nucleic acid libraries

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223414A (en) 1990-05-07 1993-06-29 Sri International Process for nucleic acid hybridization and amplification
US8030000B2 (en) 2002-02-21 2011-10-04 Alere San Diego, Inc. Recombinase polymerase amplification
US7399590B2 (en) 2002-02-21 2008-07-15 Asm Scientific, Inc. Recombinase polymerase amplification
EP2290096B1 (en) 2002-02-21 2014-11-19 Alere San Diego, Inc. Recombinase polymerase amplification using a temperature-sensitive recombinase agent
US6897069B1 (en) 2004-06-08 2005-05-24 Ambion, Inc. System and method for electroporating a sample
CA2616241C (en) 2005-07-25 2012-02-07 Asm Scientific, Inc. Methods for multiplexing recombinase polymerase amplification
US7742463B2 (en) 2005-08-18 2010-06-22 Hong Kong Applied Science And Technology Research Institute Co., Ltd. Security gatekeeper for a packetized voice communication network
CN103153960B (zh) 2010-09-21 2015-02-25 巴斯夫欧洲公司 制备取代的n-苯基羟胺的方法
EP3202918B1 (en) * 2011-04-07 2021-10-20 Abbott Diagnostics Scarborough, Inc. Monitoring recombinase polymerase amplification mixtures
WO2016054088A1 (en) * 2014-09-29 2016-04-07 Illumina Cambridge Limited Recombinase mutants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035205A2 (en) * 2006-05-04 2008-03-27 Asm Scientific, Inc. Recombinase polymerase amplification
WO2010141940A1 (en) * 2009-06-05 2010-12-09 Alere San Diego, Inc. Recombinase polymerase amplification reagents and kits
WO2013188582A1 (en) * 2012-06-15 2013-12-19 Illumina, Inc. Kinetic exclusion amplification of nucleic acid libraries

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108913700A (zh) * 2018-08-16 2018-11-30 深圳市艾伟迪生物科技有限公司 gp32单链结合蛋白的制备方法、表达基因、重组表达载体及应用
CN108913700B (zh) * 2018-08-16 2021-04-09 深圳市艾伟迪生物科技有限公司 gp32单链结合蛋白的制备方法、表达基因、重组表达载体及应用

Also Published As

Publication number Publication date
DK3201222T3 (da) 2019-06-24
KR20200026320A (ko) 2020-03-10
RU2017110582A3 (zh) 2019-04-15
KR20190037364A (ko) 2019-04-05
US20160090581A1 (en) 2016-03-31
JP2017529093A (ja) 2017-10-05
ZA201702248B (en) 2019-06-26
BR112017006542A2 (pt) 2018-01-23
CN107208075B (zh) 2021-08-24
AU2015323936A1 (en) 2017-04-20
AU2015323936B2 (en) 2021-03-11
RU2721920C2 (ru) 2020-05-25
CA2962941C (en) 2022-06-14
KR102126641B1 (ko) 2020-06-24
US20180258409A1 (en) 2018-09-13
WO2016054088A1 (en) 2016-04-07
RU2017110582A (ru) 2018-11-07
ES2729302T3 (es) 2019-10-31
SG11201702493WA (en) 2017-04-27
US9982244B2 (en) 2018-05-29
MX2017004034A (es) 2017-11-17
BR112017006542B1 (pt) 2023-11-14
CA2962941A1 (en) 2016-04-07
IL251422B (en) 2020-10-29
JP6879519B2 (ja) 2021-06-02
EP3201222A1 (en) 2017-08-09
NZ730593A (en) 2023-06-30
EP3201222B1 (en) 2019-04-10
MY182395A (en) 2021-01-23
JP2019213545A (ja) 2019-12-19
IL251422A0 (en) 2017-05-29
KR20170065028A (ko) 2017-06-12
US10344269B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
US11198854B2 (en) Modified polymerases for improved incorporation of nucleotide analogues
AU2021290289B2 (en) Modified Polymerases For Improved Incorporation Of Nucleotide Analogues
JP2022503427A (ja) ポリメラーゼ、組成物、および使用方法
US10344269B2 (en) Recombinase mutants
KR102168695B1 (ko) 재조합효소 돌연변이체

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant